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Zinc is an essential element with diverse signaling functions in the central nervous system. 
Extracellular zinc acts on a variety of receptors to modulate neurotransmission. Notably, zinc binds 
and inhibits the GluN2A subunit of NMDA receptors (NMDARs) with high affinity. Inside the 
cell, zinc also triggers diverse signaling cascades, ranging from zinc-induced gene expression to 
cell death triggered by high concentrations of zinc. To maintain sufficient signaling without tipping 
the scales towards cell death, a complex system of transporters, metalloproteins, and ion channels 
regulate the localization and concentration of zinc. The zinc transporter, ZnT3, concentrates the 
majority of loosely bound ‘labile’ zinc into synaptic vesicles from where it then is released into 
the cleft in an activity-dependent manner. Current modeling of vesicular zinc assumes that ZnT3-
dependent zinc is released and subsequently diffuses across the cleft and this is sufficient to 
account for its actions on postsynaptic targets, including NMDARs. Interestingly, the transporter 
ZnT1 is located in the postsynaptic density and binds directly to the GluN2A subunit of NMDARs, 
suggesting that ZnT1’s transport of zinc out of the cytoplasm into the extracellular space may 
contribute to NMDAR inhibition. This suggests that ZnT1 and intracellular zinc may critically 
regulate zinc inhibition of NMDARs through ZnT1’s interaction with GluN2A. To explore this 
question, we developed a novel peptide that specifically disrupts the interaction between GluN2A 
and ZnT1. We found that either disrupting ZnT1’s association with GluN2A or chelating 
intracellular zinc is sufficient to block endogenous inhibition of NMDARs, even in the presence 
of presynaptic zinc release. ZnT1, in addition to transporting cytosolic zinc, is also upregulated by 
 v 
intracellular zinc through the metal regulatory transcription factor 1. We found that increasing 
intracellular zinc is sufficient to drive upregulation of ZnT1-GluN2A interactions and subsequent 
inhibition of NMDARs. Together these data reveal a novel mechanism in which presynaptic 
release, intracellular zinc, and ZnT1 cooperatively drive inhibition of NMDARs. These findings 
add complexity to our current understanding of zinc dynamics at the synapses and provide a novel 
mechanism for modulating zinc and NMDAR signaling.  
 vi 
Table of Contents 
Preface ......................................................................................................................................... xiii 
1.0 Introduction ............................................................................................................................. 1 
1.1 Zinc Biology in the Central Nervous System ............................................................... 1 
1.2 Postsynaptic Targets of Zinc ......................................................................................... 3 
1.3 Zinc Inhibition of NMDA Receptors ............................................................................ 5 
1.4 Distribution and Function of Zinc in the Central Nervous System ........................... 7 
1.5 Zinc Toxicity ................................................................................................................. 10 
1.6 Regulation of Neuronal Zinc ....................................................................................... 14 
1.7 Zinc Transporter 1 ....................................................................................................... 17 
1.8 Dissertation Goal .......................................................................................................... 19 
2.0 Chapter 2: Synaptic Zinc Inhibition of NMDA Receptors Depends on the 
Association of GluN2A with Zinc Transporter ZnT1 ......................................................... 20 
2.1 Overview ........................................................................................................................ 20 
2.2 Introduction .................................................................................................................. 20 
2.3 Results ............................................................................................................................ 22 
2.3.1 N2AZ disrupts the binding of ZnT1 to GluN2A .............................................22 
2.3.2 Disrupting the ZnT1-GluN2A association reduces zinc inhibition of NMDAR 
currents in cortical neurons .......................................................................................29 
2.3.3 N2AZ reduces zinc inhibition in dorsal cochlear nucleus synapses ..............30 
2.3.4 N2AZ effects are limited to the ZnT1-GluN2A association ...........................35 
 vii 
2.3.5 Postsynaptic intracellular zinc is necessary for synaptic zinc inhibition of 
NMDARs ......................................................................................................................42 
2.4 Discussion ...................................................................................................................... 45 
2.5 Materials and Methods ................................................................................................ 48 
2.5.1 Experimental Design and materials .................................................................48 
2.5.2 Neuronal Cultures ..............................................................................................50 
2.5.3 Cell line culture and transfection .....................................................................50 
2.5.4 Proximity ligation assay .....................................................................................51 
2.5.5 Brain Slices .........................................................................................................52 
2.5.6 Electrophysiology ...............................................................................................52 
2.5.7 Quantitative real-time PCR (qPCR) ................................................................56 
2.5.8 Zinc efflux assay .................................................................................................56 
2.5.9 Peptide spot array and far-Western assay .......................................................57 
2.5.10 Statistical Analyses ...........................................................................................58 
3.0 Chapter 3: Zinc-dependent Upregulation of ZnT1 Enhances Zinc Inhibition of 
NMDA Receptors ................................................................................................................... 60 
3.1 Overview ........................................................................................................................ 60 
3.2 Introduction .................................................................................................................. 61 
3.3 Results ............................................................................................................................ 63 
3.3.1 Zinc Pyrithione drives MRE-regulated expression.........................................63 
3.3.2 ZnT1-GluN2A interactions are upregulated with increased intracellular zinc
 .......................................................................................................................................65 
 viii 
3.3.3 Increasing intracellular zinc leads to enhanced ZnT1-mediated zinc 
inhibition of NMDARs ................................................................................................68 
3.4 Discussion ...................................................................................................................... 70 
3.5 Material and Methods .................................................................................................. 74 
3.5.1 Neuronal cultures ...............................................................................................74 
3.5.2 MRE-Luciferase reporter assay........................................................................75 
3.5.3 Proximity ligation assay .....................................................................................75 
3.5.4 Electrophysiology ...............................................................................................76 
3.5.5 Statistical Analyses .............................................................................................77 
4.0 Discussion............................................................................................................................... 78 
4.1 Translocation of Vesicular Zinc .................................................................................. 81 
4.2 Intracellular Zinc Release ............................................................................................ 83 
4.3 Function of ZnT1-mediated Zinc Inhibition of NMDARs ........................................ 88 
4.4 ZnT1 as a Target for Neuroprotection ....................................................................... 89 
4.5 ZnT1 as a Target in NMDAR Dysfunction ................................................................ 91 
4.6 Conclusion ..................................................................................................................... 94 
Appendix A Endogenous extracellular zinc is neuroprotective against excitotoxicity ......... 95 
Appendix A.1 Overview ..................................................................................................... 95 
Appendix A.2 Results ......................................................................................................... 95 
Appendix A.3 Conclusions ............................................................................................... 100 
Appendix A.4 Methods ..................................................................................................... 101 
Appendix A.4.1 Ratiometric Zinc Imaging .............................................................101 
Appendix A.4.2 Neuronal Cultures and LDH Assay .............................................101 
 ix 
Bibliography .............................................................................................................................. 103 
 x 
List of Tables 
Table 1 Key Resources................................................................................................................ 49 
 
 xi 
List of Figures 
Figure 1 Postsynaptic Targets of Zinc ........................................................................................ 5 
Figure 2 Zinc Signaling Cascades mediating Preconditioning and Cell Death ..................... 13 
Figure 3 Generation of a ZnT1-binding Peptide (N2AZ) derived from the GluN2A C-
terminal domain. ............................................................................................................. 24 
Figure 4 N2AZ disrupts ZnT1-GluN2A C-terminal peptide binding .................................... 25 
Figure 5 Developmental profile of ZnT1 expression in cortical cultures .............................. 27 
Figure 6 N2AZ disrupts ZnT1-GluN2A association ................................................................ 28 
Figure 7 N2AZ reduces zinc inhibition of NMDAR currents in cortical cultures ................ 30 
Figure 8 N2AZ reduces ZnT3-dependent and ZnT3-independent inhibition of NMDAR 
EPSCs in DCN cartwheel cells ....................................................................................... 32 
Figure 9 ZX1 has no significant effects on NMDAR EPSCs in either KO or WT N2AZ-
treated slices .................................................................................................................... 34 
Figure 10 N2AZ does not affect zinc inhibition of AMPARs .................................................. 36 
Figure 11 N2AZ does not affect probability of glutamate release .......................................... 37 
Figure 12 N2AZ does not affect ZnT1 transport activity ........................................................ 39 
Figure 13 N2AZ does not affect exogenous zinc-mediated inhibition of GluN1/2A NMDARs
........................................................................................................................................... 41 
Figure 14 Chelating intracellular zinc reduces zinc inhibition of NMDAR EPSCs ............. 44 
Figure 15 ZnPyr treatment induces MRE-drive gene transcription...................................... 65 
Figure 16 ZnPyr increases GluN2A-ZnT1 interactions in scN2AZ but not N2AZ treated 
neurons ............................................................................................................................. 68 
 xii 
Figure 17 ZnPyr increases ZnT1-dependent zinc inhibition of NMDARs ............................ 69 
Figure 18 Proposed model of zinc-induced upregulation of ZnT1-mediated NMDAR 
inhibition .......................................................................................................................... 74 
Figure 19 Model of N2AZ Action .............................................................................................. 80 
Figure 20 Model of Zinc Transport and Release at the Synapse ............................................ 87 
Figure 21 Nanomolar extracellular concentrations of zinc are present in cortical cultures 97 
Figure 22 Extracellular zinc protects against excitotoxicity ................................................... 99 
 xiii 
Preface 
I would like to thank all the people who provided support and guidance throughout my 
graduate career. First, I would like to thank my mentors, Drs. Elias Aizenman and Thanos 
Tzounopoulos for their continued guidance and encouragement. I’m grateful for their investment 
in my development as a scientist.  I would like to thank my whole committee, Drs. Anne-Marie 
Oswald, Jon Johnson, and Amantha Thathiah for their advice and feedback as well as Dr. Richard 
Dyck for his time and effort as serving as my outside examiner. I would also like to thank all the 
members of both the Aizenman and Tzounopoulos labs for their feedback, friendship, and 
assistance over the years in lab. In particular I’d like to thank Karen Hartnett and Charlie Anderson 
for their training and assistance. I would also like to thank our collaborators, Michal Hershfinkel, 
Hila Asraf, Rajesh Khanna, Aubin Moutal, Jon Johnson, and Matt Phillips.  
The work in this dissertation would not have been possible without the support from my 
family and friends. I want to thank all my lab mates, particularly Nate Vogler, Amanda Henton, 
Yang Yeh, and Tony Schulien.  I’d also like to thank my all friends in the CNUP especially, Jake 
Wright, Jill Weeks, Jake Mann, Emily Parker, Jane Huang, Meghan Bucher, Brooke Bender, Dana 
Smith, and Karen Clark.   Finally, I would like to thank my family for their lifelong support of me 
and my goals. 
 1 
1.0 Introduction 
1.1 Zinc Biology in the Central Nervous System 
Zinc is essential for survival. Zinc deficiency is linked to a variety of adverse conditions 
including growth retardation, impaired immune function, improper skin and bone formation and 
repair, as well as cognitive disfunction (Prasad, 2003). Indeed, mutations in the principal zinc 
importer in the gut, ZIP4, lead to acrodermatitis enteropathica, a zinc-deficiency disease 
characterized by failure to thrive, severe dermatitis, hair loss, and diarrhea, which can be lethal if 
left untreated (Dufner-Beattie et al., 2007). These severe zinc deficiency outcomes are largely due 
to the impact of the essential structural and enzymatic functions of the metal. An estimated 10% 
of the human genome encodes zinc-binding proteins, which serve a diverse and rich array of roles 
in the cell (Andreini et al., 2006). Zinc catalyzes reactions of all the major classes of enzymes 
(Laitaoja et al., 2013) and stabilizes zinc-finger proteins, whose functions include transcriptional 
activation, protein folding, and RNA regulation (Laity et al., 2001). In the brain, labeling zinc with 
autometallography, more commonly referred to as Timm staining, reveals that a high concentration 
of zinc exists in a separate reserve pool of loosely bound, chelatable or “labile” zinc that is 
contained within synaptic vesicles (Timm, 1958; Haug, 1967). This points to additional, unique 
signaling roles for zinc within the central nervous system.   
 
Initial evidence for the potential role for zinc as a synaptic signaling molecule came when 
multiple groups observed that exogenous zinc application inhibited NMDA and GABAA receptors 
(Smart & Constanti, 1982; Peters et al., 1987; Westbrook & Mayer, 1987). Within this same time 
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period, evidence for vesicular release of zinc was observed following chemical stimulation as well 
as electrical stimulation of the mossy fiber pathway in hippocampal slices (Assaf & Chung, 1984; 
Howell et al., 1984). This activity-dependent increase in extracellular zinc suggested that the ion 
is released from presynaptic vesicles as a neuromodulator. In agreement with this, it was observed 
that zinc labeled with Timm-staining accumulated in the synaptic cleft over time (Pérez-Clausell 
& Danscher, 1985; 1986). Critically for the development of this field, ZnT3 (Slc30a3) was 
identified as the transporter responsible for sequestering zinc into synaptic vesicles (Palmiter et 
al., 1996; Wenzel et al., 1997). ZnT3 knockout (KO) mice showed a striking near absence of Timm 
staining in the brain, thereby demonstrating that most of labile zinc in the brain is contained within 
synaptic vesicles (Cole et al., 1999).  
 
These studies provided compelling evidence that vesicular zinc is released into the cleft 
similar to traditional neurotransmitters, however the absence of a high-affinity rapid extracellular 
zinc chelator initially made disrupting synaptic zinc signals challenging. Anderson and colleagues 
demonstrated that tricine, previously considered a preferred chelator for studying the role of 
synaptic zinc, is unable to efficiently prevent zinc from binding low-nanomolar zinc-binding sites 
due to its micromolar dissociation constant (Anderson et al., 2015).  In contrast, the chelator ZX1 
has a 1 nM zinc dissociation constant and second-order rate constant for binding zinc (Anderson 
et al., 2015). As such, ZX1 is the most appropriate chelator for investigating the effects of fast, 
transient elevations of zinc on synaptic targets with nanomolar affinity, such as GluN2A-
containing NMDARs. It has been used in conjunction with ZnT3 KO mice to better understand 
zinc’s contribution to synaptic transmission (Pan et al., 2011; Kalappa et al., 2015). 
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1.2 Postsynaptic Targets of Zinc 
Zinc regulates glutamatergic transmission through its action on all three ionotropic 
glutamate receptors. The best characterized modulatory action of zinc is its inhibition of NMDA 
receptors (NMDAR), which will be discussed in detail below (Section 1.3). AMPA receptors 
(AMPAR) are biphasically modulated by exogenous zinc application. Lower concentrations of 
zinc potentiate AMPAR responses whereas higher concentrations inhibit the receptor (Figure 
1A,B) (Rassendren et al., 1990; Bresink et al., 1996). Interestingly, chelation of zinc in acute brain 
slices reveals that zinc endogenously inhibits AMPAR EPSCs in the zinc-rich dorsal cochlear 
nucleus as well as the hippocampus. Furthermore, this effect is lost in ZnT3 knockout animals, 
showing that vesicular zinc mediates endogenous inhibition of AMPARs (Kalappa et al., 2015). 
Kainate receptors are also inhibited by zinc, with their affinity dependent on subunit composition 
(Figure 1A) (Mott et al., 2008). Isolated kainate EPSCs in CA3 neurons evoked by mossy fiber 
stimulation are potentiated when zinc is chelated. Furthermore, this effect is lost in mocha mutant 
mice, which lack zinc in the mossy fiber pathway, strongly suggesting that the action of chelators 
occurs through removal of synaptic zinc inhibition of kainate receptors (Mott et al., 2008). 
Therefore, there is significant evidence that vesicular zinc can regulate glutamatergic transmission 
through its modulation of AMPA and kainate receptors.   
 
Zinc’s modulatory actions at synapses extend beyond glutamatergic transmission. P2X 
purinergic receptors (P2XRs) are ionotropic receptors activated by extracellular ATP. Zinc 
differentially modulates P2XRs depending on which of the P2X subunits are expressed. P2X1Rs 
and P2X7Rs are inhibited by µM concentrations of extracellular zinc, whereas P2X2-4Rs exhibit 
potentiation at µM concentrations and inhibition at higher concentrations (Figure 1A,B) 
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(Nakazawa et al., 1997; Wildman et al., 1998; 1999a; b). Zinc also alters inhibitory transmission 
through its actions on GABAA and glycine receptors. GABAA receptors are allosterically inhibited 
by exogenous application of micromolar concentrations of zinc (Figure 1) (Smart & Constanti, 
1982; Westbrook & Mayer, 1987; Celentano et al., 1991; Barberis et al., 2000). However, recent 
work has suggested that endogenous zinc potentiates GABAARs, as chelation reduced GABAAR-
mediated IPSCs at cortical synapses (Kouvaros et al., 2020). Glycine receptors (GlyR), similar to 
AMPARs,  are bidirectionally modulated by zinc; exhibiting potentiation at submicromolar zinc 
concentrations (20 nM – 1 µM) and inhibition at micromolar concentrations (20 – 50 µM) (Figure 
1A,B) (Bloomenthal et al., 1994). 
 
In addition to its modulatory actions on other receptors, zinc acts as a ligand for its own 
metabotropic receptor (Figure 1C). The first evidence suggesting the existence of a metabotropic 
zinc receptor (mZnR) was obtained by Michal Hershfinkel and colleagues, demonstrating that the 
application of zinc led to IP3-dependent increases in intracellular calcium and consequent 
upregulation of the Na+/H+ exchanger in the colonocytic cell line HT29 (Hershfinkel et al., 2001). 
Multiple studies on the orphan receptor, GPR39, showed that zinc, but not its putative ligand, the 
peptide hormone obestatin, activated GPR39 (Zhang et al., 2005; Lauwers et al., 2006; Holst et 
al., 2007). Further studies revealed that siRNA against GPR39 as well as genetic knockdown of 
GPR39 prevented the intracellular calcium increase triggered by synaptic zinc release in the CA3 





Figure 1 Postsynaptic Targets of Zinc 
Legend for Figure 1: The green gradient represents the approximate concentration of zinc 
necessary for modulation each receptor. (A) Zinc-dependent inhibition has been observed for 
receptors with affinities ranging from nanomolar to high micromolar. (B) Multiple receptors that 
are inhibited by zinc are also potentiated by the ion at lower (GlyR, AMPAR, GluK3 KAR, and 
P2X2-4R) or higher (GABAAR) concentrations. (C) mZnR/GPR39 is directly activated by zinc 
1.3 Zinc Inhibition of NMDA Receptors 
The best characterized modulatory action of zinc is its inhibition of NMDARs. Initial 
studies using exogenous application of zinc found that micromolar concentrations of zinc inhibited 
NMDAR currents. These studies suggested that this inhibition had two components; a voltage-
independent block at lower µM concentrations and a voltage-dependent block at higher 
concentrations (>10 µM) (Christine & Choi, 1990; Legendre & Westbrook, 1990). Further 
investigations found that buffering with tricine removed low levels of zinc contamination in 
standard solutions that could occupy high-affinity zinc binding sites. These studies revealed  low 
nanomolar concentrations of zinc inhibit GluN2A-containing NMDARs (Paoletti et al., 1997). 
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This high affinity inhibition of GluN2A-containing NMDARs occurs through zinc binding to the 
N-terminal domain, which allosterically reduces NMDAR channel open probability via an 
enhancement of proton inhibition (Low et al., 2000; Paoletti et al., 2000; Erreger & Traynelis, 
2008). A comparable, albeit micromolar affinity allosteric binding site also exists on GluN2B’s 
N-terminal domain (Rachline et al., 2005).  
 
Endogenous zinc released from presynaptic terminals has been shown to inhibit 
postsynaptic NMDARs. Recordings of ZnT3-containing synapses in acute brain slices showed that 
chelating zinc with ZX1 disinhibits NMDARs, revealing an endogenous zinc inhibition in both the 
hippocampus and dorsal cochlear nucleus (DCN) (Pan et al., 2011; Anderson et al., 2015). Notably 
this effect is lost in ZnT3 knockout animals, suggesting vesicular zinc release is necessary for 
endogenous modulation of NMDAR by zinc (Pan et al., 2011; Anderson et al., 2015).  Moreover, 
a knock-in mutation (H128S) on the N-terminal domain of GluN2A removes high affinity zinc 
binding from NMDARs and eliminates the potentiating effect of tricine on NMDAR EPSCs in the 
hippocampus. This result convincingly reveals the physiological relevance of zinc modulation of 
NMDAR (Vergnano et al., 2014).  
 
Interestingly, an additional ZnT3-independent zinc inhibition of DNC extrasynaptic 
NMDARs was also observed (Anderson et al., 2015). In this study, multiple frequencies of 
presynaptic electrical stimulation were used to activate different pools of extrasynaptic NMDARs 
on DCN cartwheel cells. At lower frequencies, which preferentially activated receptors closest to 
presynaptic release sites, endogenous zinc inhibition was completely dependent on ZnT3. Higher 
frequencies of stimulation activated more distal NMDARs and revealed a pool of extrasynaptic 
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receptors that maintain endogenous zinc inhibition in the absence of presynaptic release. This 
suggests that an additional mechanism beyond presynaptic vesicular release may regulate 
extracellular zinc and subsequent zinc signaling.   
 
1.4 Distribution and Function of Zinc in the Central Nervous System 
Labile zinc is not uniformly distributed throughout the brain, but instead is localized to 
specific regions. Histochemical staining of zinc demonstrates that it is highly concentrated in the 
cerebral cortex, hippocampus, amygdala, and dorsal cochlear nucleus (DCN) (McAllister & Dyck, 
2017). Within these regions, ZnT3 and synaptic zinc are further restricted to a subset of 
glutamatergic neurons. For example, in the DCN, zinc is released from parallel fibers of granule 
cells, but is absent from auditory nerve terminals (Frederickson et al., 1988). Therefore, zinc in 
the DCN endogenously inhibits AMPAR EPSCs following parallel fiber, but not auditory nerve 
stimulation (Kalappa et al., 2015). This allows zinc to modulate neurotransmission in a synapse- 
and circuit-specific manner.  
 
Zinc modulates synaptic transmission and plasticity at synapses where it is released 
presynaptically. In the amygdala, synaptic zinc gates long term potentiation of principal neurons 
through its reduction of feedforward GABAergic inhibition (Kodirov et al., 2006). In the dorsal 
cochlear nucleus, zinc reduces spontaneous firing by enhancing glycinergic inhibition (Perez-
Rosello et al., 2015). Additionally, zinc inhibits presynaptic release by promoting 
endocannabinoid synthesis through its activation of mZnRs (Perez-Rosello et al., 2013).  In the 
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hippocampus, mZnR activation upregulates K+/Cl- cotransporter 2 (KCC2) activity which leads to 
hyperpolarization of GABAAR reversal potential (Chorin et al., 2011). Furthermore, zinc was 
found to regulate synaptic plasticity in the CA1 region of the hippocampus via P2X4Rs. At 
relatively low concentrations (5-50 µM), application of zinc enhanced LTP evoked by theta burst 
stimulation of Schaffer collateral fibers. The zinc effect was lost with P2XR antagonists and could 
be mimicked using a P2X4R positive allosteric modulator, suggesting that zinc facilitates LTP via 
P2X4Rs (Lorca et al., 2011).  
  
Multiple studies in the hippocampus have shown that zinc modulates long term potentiation 
(LTP) at the zinc-rich mossy fiber to CA3 synapse in the hippocampus. Zinc is required for the 
induction of a form of presynaptic LTP, which can be blocked with zinc chelation (Pan et al., 
2011). In fact, exogenous zinc is sufficient to potentiate this synapse through its activation of TrkB 
receptors (Huang et al., 2008). However, slices from ZnT3 knockout animals exhibit postsynaptic 
LTP that is absent in wildtypes controls, suggesting that vesicular zinc also precludes induction of 
postsynaptic LTP (Pan et al., 2011). Furthermore, when zinc inhibition is selectively disrupted 
using a mutant GluN2A knock in model that lacks high affinity zinc inhibition of NMDARs, only 
the magnitude of potentiation is reduced with no impact on LTP induction (Vergnano et al., 2014). 
Together these studies demonstrate that zinc drives complex signaling consequences within a 
single synapse. 
 
Synaptic zinc also regulates sensory processing. A knock-in mutation (H128S) on the N-
terminal domain of GluN2A removes high affinity zinc binding and zinc modulation of NMDARs. 
Mice with this mutation exhibit hypersensitivity to pain stimuli, suggesting endogenous zinc 
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inhibition may attenuate pain processing (Nozaki et al., 2011). Importantly, synaptic zinc 
modulates sensory processing in the auditory and somatosensory systems. Chelation of 
extracellular zinc with ZX1 in the primary auditory cortex (A1) increases the responsiveness (gain) 
of sound-evoked responses of inhibitory interneurons, and decreases the gain of pyramidal neurons 
(Anderson et al., 2017). This effect on gain is eliminated in ZnT3 KO mice. Furthermore, synaptic 
zinc regulates frequency tuning in A1 in a cell specific manner (Kumar et al., 2019). Consistent 
with these findings, ZnT3 KO mice exhibit reduced frequency discrimination compared to wild-
type controls suggesting that zinc modulation of auditory circuits is critical for normal sensory 
processing (Kumar et al., 2019). Interestingly, ZnT3 KO mice also exhibit deficits in whisker 
texture discrimination, suggesting a similar requirement of zinc for fine-tuning of somatosensory 
processing (Patrick Wu & Dyck, 2018).  
 
Sensory regions that express ZnT3 also exhibit experience-dependent changes in zinc 
content, suggesting zinc signaling may contribute to changes in response to sensory experience. 
For example whisker plucking or stimulation leads to increase or decrease respectively in synaptic 
zinc staining (Brown & Dyck, 2002; 2005; Nakashima & Dyck, 2010). Similarly, zinc levels in 
the DCN decrease following noise exposure (Kalappa et al., 2015; Vogler et al., 2020). In the 
dorsal cochlear nucleus high frequency stimulation of the ZnT3-containing parallel fibers reduces 
zinc signaling whereas low frequency stimulation increases zinc signaling. Metabotropic 
glutamate receptor activation is necessary and sufficient to induce this zinc plasticity. In fact, 
injection of a mGluR antagonist prevents noise-induced reductions in DCN zinc signaling, 
suggesting a the same mechanism of plasticity in slice preparations also occurs in vivo (Vogler et 
al., 2020). 
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1.5 Zinc Toxicity 
Zinc signaling can also trigger cell death. These pathological actions of zinc in neurons 
were first identified following the observation that exposure to extracellular zinc causes 
widespread neuronal cell death in vitro (Yokoyama et al., 1986; Choi et al., 1988). The extent of 
damage in cultured neurons varied with the concentration and duration of zinc treatment, 
suggesting a direct relationship between zinc and cell death (Choi et al., 1988). Furthermore, both 
kainate-induced seizures and ischemia were later noted to trigger zinc translocation from 
presynaptic bouton to degenerating postsynaptic cell bodies (Frederickson et al., 1989; Koh et al., 
1996). Injured animals exhibit reduced vesicular zinc staining and increased somatic staining 
compared to control animals (Frederickson et al., 1989; Koh et al., 1996; Suh et al., 2000). 
Furthermore, extracellular chelation in vivo attenuates cell death and degeneration induced by 
ischemia or traumatic brain injury, suggesting that the extracellular movement of the vesicular 
pool contributes to the zinc toxicity (Koh et al., 1996; Suh et al., 2000). 
 
A common feature of deleterious zinc signaling cascades is the generation of reactive 
oxygen species (ROS). Zinc activates 12-lipoxygenase (12-LOX) and NADPH oxidase to trigger 
ROS generation (Noh & Koh, 2000; Zhang et al., 2004). Subsequently, ROS can activate mitogen-
activated protein kinase (MAPK) cascades including the Ras/Raf/MEK/ERK and p38 MAPK 
pathways (Figure 2). Zinc-induced ERK signaling causes toxicity in cortical cultures through 
poly(ADP-ribose) polymerase activation, DNA damage, ROS production via NADPH oxidase, 
and mitochondrial hyperpolarization and dysfunction (Du et al., 2002; He & Aizenman, 2010). 
Zinc activation of p38 MAPK leads to phosphorylation of a c-terminal serine of the delayed 
rectifying voltage-gated potassium channel Kv2.1. Similarly zinc increases phosphorylation of 
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Kv2.1 at an n-terminal tyrosine through its activation of Src kinase and concurrent inhibition of 
cytoplasmic protein phosphatase ε (McLaughlin et al., 2001; Redman et al., 2007; Huang et al., 
2008; Redman et al., 2009). Together, this dual phosphorylation leads to insertion of Kv2.1 into 
the membrane, increased Kv2.1 activity, and, subsequently to caspase activation and apoptotic cell 
death by decreasing intracellular potassium concentrations (Figure 2) (Redman et al., 2009). 
Another zinc-regulated apoptotic signaling cascade is p75NTR mediated cell death in which p75NTR 
and p75NTR-associated death executor induction leads to caspase activation and neuronal 
degeneration (Figure 2) (Park et al., 2000). Intracellular zinc also triggers degeneration through 
mitochondrial dysfunction and energy failure. Following increases in the cytoplasm, zinc can 
accumulate in the mitochondria via the mitochondrial calcium uniporter (Malaiyandi et al., 2005; 
Medvedeva & Weiss, 2014). Zinc accumulation is associated with a loss of mitochondrial 
membrane potential, subsequent mitochondrial dysfunction, and ROS production (Sensi et al., 
2003; Dineley et al., 2005; Medvedeva & Weiss, 2014). Additionally zinc-mediated signaling has 
been linked to opening of the mitochondrial permeability transition pore, which triggers 
mitochondrial failure (Jiang et al., 2001; Bonanni et al., 2006). Zinc also disrupts energy 
production through its inhibition of GAPDH, thus impairing glycolysis (Sheline et al., 2000).   
 
Intracellular zinc also triggers neuroprotective signaling mechanisms at concentrations that 
are insufficient for toxicity. This process, in which a sub-lethal insult protects cells against 
subsequent lethal ones, is called preconditioning. Treating neuronal cultures with metal chaperones 
to increase intracellular zinc protects neuron against subsequent excitotoxic and ischemic insults, 
suggesting zinc itself can drive preconditioning (Wang et al., 2010; Johanssen et al., 2015). In fact, 
studies in cortical cultures found that preconditioning with sub-lethal potassium cyanide leads to 
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transient increases in labile zinc that are necessary and sufficient for neuroprotection against 
subsequent excitotoxicity. Zinc transients are triggered by protein kinase C (PKC)-facilitated 
release of zinc from metallothionein 1 and subsequent upregulation of gene expression (Figure 2) 
(Aras et al., 2009).  Similarly, ischemic preconditioning in rats leads to transient zinc increases in 
the cortex and striatum. Chelation of zinc is sufficient to abolish the neuroprotective effect. 
Furthermore, zinc induced preconditioning in cortical cultures is associated with activation of the 
p75NTR pathway and upregulation of heat-shock protein 70, via p38 and extracellular regulated 
kinase MAPK signaling (Figure 2) (Lee et al., 2008).  Sub-lethal zinc signaling also triggers 
ryanodine receptor- mediated calcium release from the endoplasmic reticulum which drives 
calcineurin-dependent redistribution of Kv2.1 channels, thus preventing apoptotic insertion of 
additional Kv2.1 channels into the membrane (Figure 2) (Schulien et al., 2016; Justice et al., 2017). 
Together these findings highlight the essential role of zinc as an intermediate in both neurotoxic 




Figure 2 Zinc Signaling Cascades mediating Preconditioning and Cell Death 
Legend for Figure 2: Increases in intracellular zinc trigger both protective (light blue) and toxic 
(gray) signaling cascades. (A) Preconditioning: Sublethal increases in intracellular zinc protect 
against subsequent cell death. PKC driven release of zinc from metallothioneins triggers 
upregulation of zinc sensitive genes. Zinc binding to ryanodine receptors (RyRs) triggers calcium 
release from ER stores and subsequent activation of calcineurin, which leads to the dispersal of 
Kv2.1 channels, thus preventing Kv2.1 insertion. ERK and p38 both activate protective HSP70 
signaling. (B) Zinc Toxicity: Kv2.1 dual phosphorylation and insertion into the membrane is 
driven by p38 and Src-driven inhibition of PTP, leading to apoptotic potassium efflux through 
Kv2.1. Zinc also activates NADPH oxidase and 12-LOX which drives the generation of toxic 
reactive oxygen species (ROS). Similarly zinc import into the mitochondria through the 
mitochondrial cation uniporter (MCU) leads to dysfunction, ROS generation, and neuronal death. 
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1.6 Regulation of Neuronal Zinc 
Intracellular and extracellular labile zinc is normally maintained at low concentrations, 
despite fluctuations that result from release from synaptic terminals. This hints towards the 
dynamic processes that regulate zinc localization and concentration. However cellular zinc is not 
static, but is regulated by complex mechanisms involving transporters, ion channels, and 
metalloproteins. These systems work in tandem to spatially and temporally regulate cellular zinc 
signaling while protecting against the activation of injurious, zinc-activated cascades. In fact, metal 
binding proteins and at least twenty-four distinct zinc transporters tightly regulate the spatial and 
temporal distribution of the metal.  
 
Metallothioneins are metal binding proteins that buffer intracellular zinc. There are four 
isoforms of metallothionein, three of which (MT-I through MT-III) are expressed in the central 
nervous system, with MT-III the primary form expressed in neurons (Aschner et al., 1997). These 
proteins contain 20 cysteine residues that can bind up to 7 zinc ions via metal-thiolate clusters 
(Maret & Krezel, 2007). MTs release zinc in response to oxidative stimuli (Maret, 1994; 1995). 
For example, the thiol oxidant 2,2’-dithiodipyridine (DTDP) causes intracellular zinc release and 
subsequent zinc-dependent cell death in cortical neurons in vitro (Aizenman et al., 2000). Nitric 
oxide, an endogenous gas, also triggers zinc release from MTs (Lin et al., 2007), likely as a result 
of its interaction with superoxide and production of peroxynitrite (Zhang et al., 2004). Inhibitors 
of NO synthase can prevent the accumulation of intracellular zinc following ischemia reperfusion 




Zinc transporters are responsible for transport of zinc across membranes. There are two 
families of zinc transporters, ZIP and ZnTs, both of which are part of the broader solute carrier 
family of transporters. Zrt, Irt-like proteins (ZIPs) are zinc transporters named for the first 
homologs of the broad family of metal transports discovered in Saccharomyces cerevisiae (Zhao 
& Eide, 1996a; b) and Arabidopsis thaliana respectively (Eide et al., 1996). There are 14 ZIP 
transporters in mammals encoded by the genes SLC39A1-14, which transport zinc from the 
extracellular space or subcellular organelles into the cytoplasm. They are predicted to have 8 
transmembrane domains with extracytoplasmic N- and C-termini, and form homo- and 
heterodimers in the membrane. Initial characterization of ZIPs suggested that they transport zinc 
in a temperature- and concentration-dependent manner (Gaither & Eide, 2000). ZIP sequences lack 
ATP-binding sites, which suggests that they are not active transporters, but instead act through 
secondary transport or facilitated diffusion (Gaither & Eide, 2001). From the structure of  the 
bacterial homolog BbZIP, it was hypothesized that zinc transport by the ZIP family is mediated 
via a rigid rocking mechanism that alternatively exposes the binuclear metal center to the 
cytoplasm and extracellular space (Zhang et al., 2017). 
 
ZnTs transport zinc from the cytoplasm to the extracellular space or subcellular organelles. 
They are part of the cation diffusion facilitator (CDF) family of proteins. Since the initial discovery 
of ZnT1, an additional 9 ZnTs have been identified (ZnT2-ZnT10). Recently the protein 
TMEM163, also known as synaptic vesicle 31, was found to extrude zinc. Furthermore, sequence 
alignment and phylogenetic analysis place TMEM163 in the CDF family of proteins. Therefore 
TMEM163 has been proposed to be a new member of the ZnT family, ZnT11 (Sanchez et al., 
2019). ZnTs are thought to function as proton antiporters. In agreement with this, disruption of the 
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vacuolar-type H+ ATPase blocks ZnT-mediated zinc transport into intracellular vesicles, 
suggesting that ZnT function requires a proton gradient. Furthermore, ZnT expression increases 
the rate of alkalization of intracellular vesicles, indicating that ZnTs promote efflux of protons 
(Ohana et al., 2009; Golan et al., 2019). A recent study has provided a high-resolution structure of 
human ZnT8, revealing, for the first time, a plausible mechanism for the Zn2+/H+ exchange 
mechanism in a mammalian zinc transporter (Xue et al., 2020). By resolving both the inward 
(cytosolic) and outward (luminal) facing states of the transporter, the results from this study 
suggest a simple two-state model for zinc transport. In this model, ZnT8, functions as a dimer and 
alternates between inward and outward facing states via large structural rearrangements of the 
transmembrane domain, housing the zinc ion in a differential, pH-dependent manner.  The lower 
luminal pH induces the release of zinc from the outward-facing side, while the higher pH of the 
cytosolic environment increases the affinity of the primary binding site of the outward-facing state 
for the metal (Xue et al., 2020). 
 
Intracellular zinc regulates transcription of zinc regulatory proteins, including transporters. 
Metal-regulated gene transcription was first observed with metallothionein-1 (MT-1), a metal-
binding protein involved in zinc homeostasis and protection against oxidative stress. Mice injected 
with zinc or cadmium exhibited increased MT-1 mRNA expression in multiple tissues (Durnam 
& Palmiter, 1981). Further characterization of the MT-1 gene identified a 12 base pair DNA motif 
in the promoter region that was necessary for metal responsiveness, and thus was named metal 
response element (MRE) (Carter et al., 1984; Stuart et al., 1984; Searle et al., 1985). Shortly 
thereafter, a zinc-inducible transcription factor was found that bound MRE to induce gene 
transcription (Westin & Schaffner, 1988). Upon zinc binding, this metal regulatory transcription 
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factor (MTF-1) rapidly translocates to the nucleus and binds to DNA (Dalton et al., 1997; 
Smirnova et al., 2000). MTF-1 upregulates transcription of multiple gene targets including MT-II, 
MT-III and ZnT1. This transcriptional pathway allows the cell to maintain stable zinc 
concentrations in the face of fluctuating zinc levels.   
 
1.7 Zinc Transporter 1 
ZnT1 was the first mammalian zinc transporter identified based on its ability to confer 
protection against zinc toxicity (Palmiter & Findley, 1995). It is an essential gene for development, 
as homozygous knockout of ZnT1 is embryonic lethal (Andrews et al., 2004). It is located in the 
plasma membrane and protects cells against zinc toxicity through its extrusion of zinc out of the 
cell (Palmiter, 2004). Furthermore, it dynamically responds to intracellular zinc concentrations to 
increase or decrease zinc efflux. When intracellular zinc increases it binds MTF-1 to upregulate 
ZnT1 expression (Langmade et al., 2000).  Conversely, ZnT1 surface expression is downregulated 
via endocytosis and degradation of the transporter under zinc-deficient conditions, leading to 
decreased efflux from the cytoplasm. ZnT1 endocytosis is regulated, in part, through N-
glycosylation of asparagine 299 of the protein (Nishito & Kambe, 2019).   
 
ZnT1, in addition to its role in transporting zinc, also regulates voltage gated calcium 
channels. The C-terminal domain of ZnT1 binds to the  subunit of L-type calcium channels 
(LTCC). This association reduces in LTCC current by decreasing trafficking of the 1 subunit to 
the membrane (Levy et al., 2009). Furthermore, expression of the C-terminal domain of ZnT1 is 
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sufficient to drive this reduction in LTCC current, indicating that this effect is independent of zinc 
transport (Shusterman et al., 2017). Given that LTCCs mediate zinc influx, ZnT1-dependent 
reduction in LTCC suggests a unique mechanism in which the same protein that removes zinc 
from the cytoplasm also prevents further influx. In addition to its modulation of LTCCs, ZnT1 also 
regulates Ras/Raf/MEK/ERK signaling (Jirakulaporn & Muslin, 2004) by promoting Raf-1 
signaling through ZnT1’s interaction with the N-terminal regulatory domain. This enhancement of 
Raf-1 signaling upregulates T-type calcium channel expression on the plasma membrane and 
subsequently increases calcium currents (Mor et al., 2012). These findings show that ZnT1 protein 
interactions are associated with functional changes in both calcium and zinc signaling.  
 
ZnT1 is found throughout the brain with significant overlap in expression with high zinc 
concentration and ZnT3 expression (Sekler et al., 2002). This suggests that ZnT1 may contribute 
to zinc homeostasis at synapses. Indeed, ZnT1 is localized to the postsynaptic density in 
hippocampal neurons (Sindreu et al., 2014b). Furthermore, ZnT1 binds directly to the C-terminal 
domain of the GluN2A subunit of NMDARs (Mellone et al., 2015). Overexpression or silencing 
of ZnT1 leads to an increase or decrease in spine size, respectively. Given that NMDAR activation 
is a significant regulator of synaptic strength and spine dynamics (Segal, 2005; Sala & Segal, 
2014), ZnT1’s association with NMDAR may be driving changes in spine morphology by 
regulating NMDAR function.  
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1.8 Dissertation Goal 
The majority of studies of zinc signaling in synapses have focused on the vesicular 
transporter ZnT3, despite the complex system of transporters that regulate zinc localization and 
concentration in neurons. Indeed, there is evidence that ZnT3-independent zinc pools influence 
synaptic functions, including glycinergic and NMDAR-mediated transmission (Anderson et al., 
2015; Perez-Rosello et al., 2015). ZnT1 is located postsynaptically and directly binds to the highly 
zinc-sensitive GluN2A subunit of NMDARs, thus positioning ZnT1 to directly regulate zinc 
inhibition of NMDARs (Mellone et al., 2015). The goal of this dissertation is to determine the role 
of ZnT1 in zinc inhibition of NMDARs. To address this question, we developed a peptide to 
specifically interfere with the interaction between ZnT1 and the GluN2A subunit. Using this 
peptide, we determined that ZnT1 is crucial for endogenous zinc inhibition of NMDARs in cortical 
cultures and acute slices of the DCN (Chapter 2). Furthermore, we revealed a zinc-dependent 
mechanism that regulates zinc inhibition of NMDARs via upregulation of ZnT1 (Chapter 3). These 
results challenge the conventional understanding of how zinc inhibits synaptic NMDARs and 
demonstrates that presynaptic release and a postsynaptic transporter organize zinc into distinct 
microdomains to modulate NMDAR neurotransmission.  
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2.0 Chapter 2: Synaptic Zinc Inhibition of NMDA Receptors Depends on the Association of 
GluN2A with Zinc Transporter ZnT1  
2.1 Overview 
The NMDA receptor (NMDAR) is inhibited by synaptically released zinc. This inhibition 
is thought to be the result of zinc diffusion across the synaptic cleft, and subsequent binding to the 
extracellular domain of the NMDAR. However, this model fails to incorporate the observed 
association of the highly zinc-sensitive NMDAR subunit GluN2A to the postsynaptic zinc 
transporter ZnT1, which moves intracellular zinc to the extracellular space. Here, we report that 
disruption of ZnT1-GluN2A association by a cell-permeant peptide strongly reduced NMDAR 
inhibition by synaptic zinc in mouse dorsal cochlear nucleus synapses. Moreover, synaptic zinc 
inhibition of NMDARs required postsynaptic intracellular zinc, suggesting that cytoplasmic zinc 
is transported by ZnT1 to the extracellular space in close proximity to the NMDAR. These results 
demonstrate that presynaptic release and a postsynaptic transporter organize zinc into distinct 
microdomains to modulate NMDAR neurotransmission. 
2.2 Introduction 
Zinc is a neuromodulator that regulates glutamatergic, GABAergic and glycinergic 
synaptic transmission (Xie & Smart, 1991; Vogt et al., 2000; Hirzel et al., 2006; Vergnano et al., 
2014; Anderson et al., 2015; Kalappa et al., 2015; Perez-Rosello et al., 2015), short- and long-
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term synaptic plasticity (Huang et al., 2008; Pan et al., 2011; Perez-Rosello et al., 2013; Vergnano 
et al., 2014; Kalappa & Tzounopoulos, 2017; Eom et al., 2019), auditory processing, and acuity 
for sensory stimulus discrimination (Patrick Wu & Dyck, 2018; Kumar et al., 2019). The zinc 
transporter ZnT3 (Slc30a3) packages zinc into presynaptic vesicles of large populations of 
excitatory neurons in many brain regions, including the cerebral cortex, hippocampus, amygdala, 
and dorsal cochlear nucleus, (McAllister & Dyck, 2017). During synaptic activity, vesicular zinc 
is released from ZnT3-containing terminals (Assaf & Chung, 1984; Vogt et al., 2000) and diffuses 
across the synaptic cleft (Anderson et al., 2015) to modulate a number of postsynaptic receptors 
(Ruiz et al., 2004; Besser et al., 2009; Kalappa et al., 2015; Perez-Rosello et al., 2015), including 
the highly zinc-sensitive N-methyl-D-aspartate glutamatergic receptor (NMDAR) (Peters et al., 
1987; Paoletti et al., 1997; Jo et al., 2008; Vergnano et al., 2014; Anderson et al., 2015).  
 
GluN2A-containing NMDARs are the major postsynaptic targets of synaptically-released 
zinc due to their sensitivity to nanomolar concentrations of extracellular zinc, which inhibit 
receptor function (Paoletti et al., 1997). It is generally accepted that zinc release alone provides 
sufficient accumulation of the metal in the synaptic cleft to account for the observed zinc inhibition 
of GluN2A-containing NMDARs (Pan et al., 2011; Vergnano et al., 2014; Anderson et al., 2015). 
However, this model only takes into account ZnT3’s contribution to activity-dependent vesicular 
zinc inhibition of NMDARs, when, in fact, there are 24 known unique zinc transporters (10 Slc30a 
and 14 Slc39a) (Kambe et al., 2014) that may be involved in zinc’s spatial distribution in synapses. 
Little is known, however, how zinc transporters other than ZnT3 influence synaptic zinc’s actions 
upon its receptor targets. 
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ZnT1 (Slc30a1), a cell membrane transporter that shuttles zinc from the cytoplasm to the 
extracellular space, not only localizes to the postsynaptic density (Sindreu et al., 2014a), but also 
binds directly to the GluN2A subunit of NMDARs (Mellone et al., 2015). This positions ZnT1, in 
concert with the presynaptic ZnT3 transporter, as a likely co-regulator of synaptic zinc 
concentration and function in the synaptic cleft. Here, we developed a peptide to disrupt ZnT1-
GluN2A binding and used ZnT3 null mice and zinc chelation to assess the contribution of ZnT1 
into synaptic actions of zinc. Our studies reveal a novel interplay between ZnT3- and ZnT1-
dependent zinc transport to inhibit NMDAR-mediated neurotransmission. 
2.3 Results 
2.3.1 N2AZ disrupts the binding of ZnT1 to GluN2A 
To study the effect of ZnT1 on zinc inhibition of NMDARs, we designed a peptide aimed 
at disrupting the ZnT1-GluN2A interaction. We first constructed a peptide spot array spanning 74 
amino acids of the C-terminal domain (residues 1390-1464) of mouse GluN2A (Uniprot# P35436), 
previously shown to be necessary for ZnT1-GluN2A binding (Mellone et al., 2015). The array 
consisted of sixty-one 15-mers, each sequentially overlapping by 14 amino acids, similar to 
procedures described earlier by our groups for other protein-protein interaction systems (Brittain 
et al., 2011; Yeh et al., 2017). Next, we probed the peptide spot arrays with flag-tagged ZnT1-
enriched cell lysates and then visualized and quantified ZnT1 binding with immunofluorescence 
against the flag tag (Figure 3A). This approach identified three regions of significant ZnT1 
binding, spanning peptide numbers 2-8, 40-42, and 48-52 in Fig. 3A, B. We focused on the 
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broadest binding peak (peptides 2-8, Figure 3B, in red), which included a common 9 amino acid 
sequence among the peptides with high ZnT1 binding (NDSYLRSSL, corresponding to GluN2A 
residues 1397-1406). Notably, this 9 amino acid sequence from the mouse GluN2A is conserved 
in both the rat and human GluN2A sequences (isoform 1, Uniprot# rat: Q00959, human: Q12879). 
This peptide and its scrambled control (SNLSDSYLR; Figure 3B, inset) were conjugated to the 
trans-activator of transcription (TAT) cell-penetrating peptide (YGRKKRRQRRR) to endow 
them with membrane permeability. As it was designed to prevent ZnT1-GluN2A binding, the 
peptide, and its scrambled control, will herein be referred to as N2AZ and scN2AZ, respectively. 
To confirm that N2AZ prevents GluN2A-derived sequences from binding to ZnT1, the peptide 
spot assay was repeated in the presence of either N2AZ or scN2AZ (100 µM). We noted that N2AZ 
significantly reduced ZnT1 binding to the spot array, when compared to scN2AZ control (Figure 




Figure 3 Generation of a ZnT1-binding Peptide (N2AZ) derived from the GluN2A C-terminal domain. 
Legend for Figure 3: (A) A peptide spot array was composed of sixty-one 15-mers spanning the 
GluN2A C-terminus region (residues 1390–1464) with 14 amino acid overlapping sequential 
sequences used to identify regions of high ZnT1 binding. A representative array is shown with 
corresponding peptide numbers denoted below the blot.  Sequences for each peptide number are 
shown in (B). The peptides denoting the broadest ZnT1 binding region are outlined in red. (B) 
Mean ± SEM (n=4) of ZnT1 binding intensity for each GluN2A-derived peptide. Inset: Peptide 
sequences flanking a region of high ZnT1 binding (peptide numbers 2-8, in red) were used to 
determine the shared peptide sequence of the ZnT1 binding peptides. Sequence in light gray 
represents the cell-permeable HIV trans-activator of transcription domain (TAT) sequence. The 
red sequence represents final peptide, and the blue represents its scrambled control. Both peptides 
were conjugated to TAT to create our experimental (N2AZ) and control (scN2AZ) peptides.  
 25 
 
Figure 4 N2AZ disrupts ZnT1-GluN2A C-terminal peptide binding 
Legend for Figure 4: Quantification of peptide spot arrays of GluN2A C-terminus region (residues 
1390-1464) using the same peptide segments as in Fig. 3 Bar graphs show the summary of ZnT1 
binding intensity for each GluN2A-derived peptide in the presence of either N2AZ (red, 100 µM) 
or scN2AZ (blue, 100 µM). *Significant differences in ZnT1 binding for each peptide number are 
noted (multiple unpaired t-test, p < 0.05, multiple comparisons, Holm-Sidak method). Mean ± 








Next, we utilized rat cortical cultures to determine whether N2AZ treatment was sufficient 
to disrupt ZnT1-GluN2A association in neurons. First, we verified that ZnT1 mRNA was indeed 
expressed in cortical cultures using quantitative PCR. We observed that ZnT1 mRNA expression 
increased over the first four weeks in vitro (Figure 5), paralleling the established developmental 
profile of GluN2A expression previously obtained in the same preparation by our group (Sinor et 
al., 2000). Next, we quantified ZnT1-GluN2A interactions in the cultures using a proximity 
ligation assay (PLA, see Materials and Methods). This method results in fluorescent puncta when 
target proteins are within 40 nm of one another, thus revealing protein-protein interactions (Zhu et 
al., 2017). Cultures (21 - 25 days in vitro, DIV) were treated overnight in either scN2AZ or N2AZ 
(3 µM) prior to performing PLA. To visualize neurons, cultures were immunostained against 
MAP2. We observed that PLA puncta localized along neuronal dendrites, consistent with previous 
findings localizing ZnT1 to the postsynaptic density (Figure 6A) (Sindreu et al., 2014a; Mellone 
et al., 2015). Importantly, we found that N2AZ treatment significantly reduced the number of PLA 
puncta, when compared to sister cultures treated with scN2AZ (Figure 6B, paired t-test, p = 0.004; 
n= 4 coverslips). These results indicate that N2AZ effectively disrupts ZnT1-GluN2A interactions 




Figure 5 Developmental profile of ZnT1 expression in cortical cultures 
Legend for Figure 5: qPCR measurements of ZnT1 RNA expression in mouse cortical cultures 










Figure 6 N2AZ disrupts ZnT1-GluN2A association 
Legend for Figure 6: (A) Representative images of rat cortical cultures following proximity 
ligation assay (PLA) between GluN2A and ZnT1. The PLA immunofluorescently labeled sites of 
interaction between GluN2A and ZnT1 (white puncta). Additionally, MAP2 is 
immunofluorescently labeled in red to visualize neuron morphology. Scale bar: 20 µm. Top row 
shows PLA assay following overnight exposure to 3 µM scN2AZ, while bottom row shows PLA 
assay following 3 µM N2AZ treatment. Insets show the localization of PLA puncta along a MAP2 
stained dendrite. (B) Quantification of PLA puncta per 100 µm2 in sister cortical cultures treated 
overnight with 3 µM N2AZ or scN2AZ show that N2AZ significantly reduced the number of 
ZnT1-GluN2A interactions compared to scN2AZ (Paired t-test, p = 0.0044, n = 4). Gray filled 





2.3.2 Disrupting the ZnT1-GluN2A association reduces zinc inhibition of NMDAR currents 
in cortical neurons 
Zinc inhibits GluN2A-containing NMDARs through its high-affinity binding site on the 
extracellular, N-terminal domain of the GluN2A subunit (Paoletti et al., 1997; Nozaki et al., 2011; 
Anderson et al., 2015). As ZnT1 shuttles neuronal intracellular zinc to the extracellular space 
(Shusterman et al., 2014), we hypothesized that ZnT1 functionally localizes zinc in close 
proximity to its GluN2A binding site, and thereby, contributes to the inhibition of NMDARs by 
the metal. To test this hypothesis, we treated cortical cultures (DIV 18-22) overnight with N2AZ 
or scN2AZ (3 µM) prior to recording NMDAR-receptor mediated currents. These currents were 
evoked by photolytic uncaging of caged glutamate (4-Methoxy-7-nitroindolinyl-caged-L-
glutamate, 40 µM) along the dendrites of neurons (Figure 7A). Neurons were held at -70 mV in 
the absence of extracellular Mg2+ to prevent block of NMDARs, and in the presence of DNQX (20 
µM) to block AMPAR currents. Zinc inhibition was determined by measuring the extent of 
NMDAR EPSC potentiation following application of the fast, high affinity, zinc-specific cell-
impermeant (extracellular) zinc chelator ZX1 (3 µM)  (Pan et al., 2011; Anderson et al., 2015; 
Kalappa et al., 2015). We observed that in cells previously treated with the scN2AZ control, 
extracellular zinc chelation with ZX1 produced a potentiation of NMDAR-mediated currents 
(Figure 7B-C, 37.40 ± 11.63%, n=10, p = 0.02, paired t-test of peak responses before and after 
ZX1), likely reflective of background tonic zinc present in the cultures. In contrast, N2AZ 
prevented ZX1 potentiation of NMDAR-mediated currents (Figure 7B-C, 1.34 ± 3.48%, n=9, p = 
0.62, paired t-test of peak responses before and after ZX1; scN2AZ versus N2AZ, p = 0.01, 
unpaired t-test). This result indicates that ZnT1 binding to GluN2A is critical for endogenous zinc 




Figure 7 N2AZ reduces zinc inhibition of NMDAR currents in cortical cultures 
Legend for Figure 7: (A) Representative image of a neuron in cortical culture filled with Alexa 
548 during whole cell recording. Blue asterisk represents one example location of laser photolysis 
of MNI-caged glutamate (40 µM, 1 ms pulse) used to evoke EPSCs. (B) Sample traces of NMDAR 
currents, averaged over 4 sweeps, evoked by photolysis of MNI-caged glutamate in cultured 
cortical neurons held at -70 mV in Mg2+ free solution, before (blue scN2AZ, red N2AZ; 3 µM, 
treated overnight) and after application of ZX1 (black; 100 µM). (C) ZX1 potentiation of NMDAR 
currents was significantly diminished in N2AZ-treated cells versus scN2AZ control (unpaired t-
test, p = 0.01, n = 10,9). Bar graphs represent the average potentiation of responses 5 minutes after 
ZX1 application. Error bars indicate mean ± SEM. 
2.3.3 N2AZ reduces zinc inhibition in dorsal cochlear nucleus synapses 
In order to investigate whether ZnT1 contributes to synaptic zinc mediated inhibition of 
NMDARs, we performed electrophysiological recordings in acutely-prepared brain slices of the 
dorsal cochlear nucleus (DCN), an auditory brainstem nucleus containing parallel fibers with zinc-
 31 
rich synaptic terminals (Frederickson et al., 1988). In response to parallel fiber stimulation, 
synaptic zinc inhibits both NMDA and AMPA-mediated synaptic currents in cartwheel cells 
(Anderson et al., 2015; Kalappa et al., 2015), interneurons in the molecular layer of the DCN. 
NMDAR excitatory postsynaptic currents (EPSCs) were isolated by voltage-clamping cartwheel 
cells at +40 mV to relieve the Mg2+ block, while recording in the presence of DNQX (20 µM). 
Slices were incubated with either scN2AZ or N2AZ (3 µM) for at least 1 hour prior to ZX1 (100 
µM) application. We stimulated parallel fibers at 20 Hz, a frequency where zinc inhibition of 
NMDARs is entirely ZnT3-dependent in DCN parallel fiber synapses (Anderson et al., 2015). We 
found that N2AZ reduced the ZX1 potentiation of NMDAR EPSCs, when compared to scN2AZ 
(Figure 8A-C; N2AZ: 19.39 ± 5.82%, n=14 vs. scN2AZ: 47.30 ± 10.14% n = 9, unpaired t-test, 
p= 0.02). This result indicates that, contrary to the current model, synaptically-released zinc release 
alone cannot account for the inhibition of NMDARs by the metal. Instead, this result suggests that 
the ZnT1-GluN2A association is crucial for the synaptic zinc inhibition of NMDARs. 
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Figure 8 N2AZ reduces ZnT3-dependent and ZnT3-independent inhibition of NMDAR EPSCs in DCN 
cartwheel cells 
Legend for Figure 8: (A, D) Sample traces of NMDAR EPSCs, averaged over 5 sweeps, evoked 
in cartwheel cells in response to five pulses at 20 Hz (A) or 100 Hz (D) stimulation frequency of 
parallel fibers. Before (blue scN2AZ, red N2AZ; 3 µM, treated ≥1 hour prior to recording) and 
after application of ZX1 (black; 100 µM). (B, E) Time course of NMDAR EPSCs, normalized to 
a 5-minute baseline prior to addition of ZX1. Dotted line marks 100% of baseline. (C, F) Group 
data show ZX1 potentiation of EPSCs was significantly reduced in N2AZ- versus scN2AZ-treated 
slices for 20 Hz stimulation (unpaired t-test, p= 0.02, n = 14,9) and 100 Hz stimulation (unpaired 
t-test, p = 0.02, n = 14,9). Bar graphs represent the average potentiation of responses 10-15 minutes 
after ZX1 application. Error bars indicate mean ± SEM. 
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To control for potential off-target actions of N2AZ, we next validated that the actions of 
the peptide on synaptic zinc inhibition of NMDAR depend on ZnT3.  To do this, we tested the 
effects of ZX1 on NMDAR EPSCs in N2AZ-treated slices obtained from ZnT3 null (KO) mice, 
lacking synaptic zinc, and wild-type (WT) littermates. As expected (Anderson et al., 2015), ZX1 
had similar, albeit very modest, effects on NMDAR EPSCs in both KO and WT N2AZ-treated 
slices (Figure 9, KO: 11.9 ± 6.90% potentiation, n=6; WT: 5.60 ± 4.38% potentiation, n=8).  This 
finding indicates that in the absence of vesicular zinc, dissociating Glun2A from ZnT1 is of no 












Figure 9 ZX1 has no significant effects on NMDAR EPSCs in either KO or WT N2AZ-treated slices 
Legend for Figure 9: (A) Sample traces of NMDAR EPSCs at +40 mV, average of 5 sweeps, 
evoked in N2AZ treated slices (3 µM, treated ≥1 hour prior to recording) with 20 Hz stimulation 
of parallel fibers before (gray WT,  purple ZnT3 KO) and after application of ZX1 (black, 100 
µM). (B) Time courses of NMDAR EPSCs normalized to a 5-minute baseline in WT and ZnT3 
KOs showing the effect of ZX1 on NMDAR EPSCs. Dotted line marks 100% of baseline. (C) 
Group data show ZX1 potentiation of EPSCs was not significantly different between WT (n = 8) 
and KOs (n = 6). Bar graphs represent the average potentiation of responses 10-15 minutes after 
ZX1 application. Dotted line indicates average potentiation measured following treatment of WT 
mice with scN2AZ as reported in Figure 8. Error bars indicate mean ± SEM. 
 
Interestingly, stimulation of parallel fibers at higher frequencies (100 Hz – 150 Hz) 
previously uncovered a residual, ZnT3-independent component of zinc inhibition of NMDAR 
EPSCs (Anderson et al., 2015). As such, we next evaluated the contribution of the ZnT1-GluN2A 
interaction to this additional mode of zinc inhibition. We found that N2AZ treatment indeed 
eliminated ZX1 potentiation of NMDAR EPSCs at 100 Hz stimulation frequency, suggesting that 
ZnT1-GluN2A interaction is also required for high stimulation frequency, ZnT3-independent zinc 
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inhibition (Figure 8D-F, 1.95 ± 4.33%, n=14, p = 0.45, paired t-test of responses before and after 
ZX1). Taken together, our results indicate ZnT1-GluN2A binding is critical for both ZnT3-
dependent and high stimulus frequency, ZnT3-independent inhibition of NMDARs. 
 
2.3.4 N2AZ effects are limited to the ZnT1-GluN2A association 
In addition to blocking NMDAR, synaptically released zinc inhibits AMPAR EPSCs in 
cartwheel cells (Kalappa et al., 2015). To test whether the aforementioned actions of N2AZ are 
specific for NMDAR ESPCs, we measured the effect of N2AZ and scN2AZ on zinc inhibition of 
AMPAR EPSCs. ZX1 potentiated AMPAR EPSCs to a similar extent regardless of the treatment 
with either scN2AZ or N2AZ (Figure 10; scN2AZ : 30.3 ± 10.24%, n=6; N2AZ : 29.3 ± 6.70, n=6; 
unpaired t-test p = 0.93), with the extent of AMPAR-mediated current potentiation being 
comparable to that observed in previous studies (Kalappa et al., 2015). These results indicate that 






Figure 10 N2AZ does not affect zinc inhibition of AMPARs 
Legend for Figure 10: (A) Sample traces of AMPAR EPSCs in cartwheel cells held at -70 mV, 
average of 5 sweeps, in response to single pulse parallel fiber stimulation (blue scN2AZ, red 
N2AZ; 3 µM, treated ≥ 1 hour prior to recording) and after application of ZX1 (black; 100 µM) 
(B) Group data of ZX1 potentiation of AMPAR EPSCs (n = 3) in scN2AZ and N2AZ treated 
groups. Bar graphs represent the average potentiation of responses 10-15 minutes after addition of 
ZX1. There were no differences in ZX1 potentiation of AMPAR EPSCs between these groups. 
 
We also evaluated whether a change in presynaptic release of glutamate contributes to the 
observed actions of N2AZ on NMDAR-mediated synaptic currents. We used two independent 
measures of release probability, paired-pulse ratio (PPR) and the coefficient of variance (CV). We 
measured PPR by applying two stimuli in rapid succession (50 ms interpulse interval) and 
obtaining the amplitude ratio of the second EPSC to the first. We calculated CV as the standard 
deviation of a series of EPSCs divided by their mean amplitude. Both measures vary inversely 
with probability of release. We found that scN2AZ and N2AZ altered neither PPR nor CV (Figure 
11, PPR; scN2AZ: 2.18 ± 0.26, n=3; N2AZ: 2.29 ± 0.07, n=5; unpaired t-test, p = 0.59, CV; 
scN2AZ: 0.28 ± 0.030, n=3; N2AZ: 0.26 ± 0.031, n=5; unpaired t-test, p = 0.76). As such, N2AZ’s 
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effects on zinc inhibition of NMDAR-mediated synaptic currents are not associated with changes 
in presynaptic release probability. 
 
 
Figure 11 N2AZ does not affect probability of glutamate release 
Legend for Figure 11 (A) Sample traces of paired-pulse of AMPAR EPSCs (50 ms interstimulus 
interval) showing similar facilitation in scN2AZ- (blue, top) and N2AZ- treated slices (red, 
bottom). (B, C) Group data of paired pulse ratio (PPR, D) and coefficient of variance (CV, E) 
show no effects in presynaptic glutamate release between scN2AZ- and N2AZ-treated slices (n = 
3). 
 
To control for potential effects of the peptide on the ZnT1 transporter activity, we next 
examined whether N2AZ modifies transport itself. Following intracellular zinc loading, we 
measured decreases in intracellular zinc levels over time as a readout of zinc transport in HEK293 
cells previously transfected with a plasmid encoding ZnT1, or with an empty vector. We used 
FluoZin-3 fluorescence to measure intracellular zinc levels. FluoZin-3-loaded cells were briefly 
treated with zinc pyrithione (1 µM Zn2+, 5 µM sodium pyrithione) to increase intracellular zinc 
concentrations until the fluorescent signal reached a maximum, steady-state level (Figure 12A). 
Zinc efflux was then measured as the decrease in FluoZin-3 fluorescence (Devinney et al., 2005) 
 38 
(Figure 12A). As expected, ZnT1-expressing cells showed significantly more zinc efflux than 
vector transfected controls (Figure 12B, one-way ANOVA, p = <0.0001, Tukey multiple 
comparisons N2AZ versus vector, scN2AZ versus vector, p = <0.0001). However, the rate of zinc 
efflux was not different in ZnT1-expressing cells treated with either scN2AZ or N2AZ (-
0.0002273 (F/F0)/s, n=5) or scN2AZ (-0.0002327 (F/F0)/s, n=4) (Tukey multiple comparisons, 
N2AZ versus scN2AZ, p = 0.97), indicating that N2AZ’s actions on zinc inhibition of NMDARs 












Figure 12 N2AZ does not affect ZnT1 transport activity 
Legend for Figure 12: (A) Example traces of zinc-sensitive FluoZin-3 fluorescence from one set 
of coverslips of HEK293 cells transfected with vector (black), transfected with ZnT1 in addition 
to scN2AZ treatment (blue), or transfected with ZnT1 in addition to N2AZ treatment (red). After 
initial baseline fluorescence was obtained, zinc pyrithione (1 µM Zn2+, 5 µM pyrithione) was 
added to increase intracellular zinc (black bar, above). Then zinc pyrithione was washed out and 
zinc efflux was measured as the decrease in FluoZin-3 fluorescence. Box indicates time epoch 
where zinc efflux was measured. (B) Average of all experiments showing the change in FluoZin-
3 fluorescence following washout of zinc pyrithione (C) The rates of zinc efflux were determined 
by the slope of the average fluorescence traces in G. As expected, ZnT1-transfected N2AZ and 
scN2AZ treated cells exhibited greater zinc efflux compared to vector-transfected controls (one-
way ANOVA, p = <0.0001, Tukey multiple comparisons N2AZ (n =4) versus vector (n=5), 
scN2AZ (n=4) versus vector, p = <0.0001); however, there was no difference in zinc efflux 
between scN2AZ and N2AZ (Tukey multiple comparisons, N2AZ versus scN2AZ, p = 0.97). 
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To control for potential effects of N2AZ on NMDAR affinity for zinc itself, we measured 
NMDAR inhibition by exogenous zinc application onto tsa201 cells previously transfected with 
plasmids encoding GluN1 and GluN2A. Exogenous, extracellular zinc was applied across a wide 
range of concentrations (1-300 µM) using a multi-barreled rapid-perfusion system while recording 
glutamate (1 mM)-evoked steady-state GluN1/2A receptor current. The calculated IC50’s for zinc 
block in vehicle, scN2AZ-, or N2AZ-treated cells were not different across the three treatments 
(Figure 13, IC50 in nM; Vehicle: 21.8 ± 2.1, n = 5; scN2AZ: 23.4 ± 2.4, n = 5; N2AZ = 25.6 ± 2.2 
n = 5, Ordinary one-way ANOVA, p = 0.4996), indicating that N2AZ does not affect zinc’s affinity 
for GluN1/2A receptors. Taking all of these results together, we conclude that N2AZ reduces zinc 
inhibition of NMDARs by disrupting the ZnT1-GluN2A interaction, without affecting glutamate 
release, ZnT1-dependent zinc transport, or zinc affinity for GluN1/2A receptors. Moreover, these 







Figure 13 N2AZ does not affect exogenous zinc-mediated inhibition of GluN1/2A NMDARs 
Legend for Figure 13 (A) Sample traces of NMDAR currents following fast application of 
glutamate (1 mM, Glu, black bar, above) in tsA201 cells transfected with GluN1/2A with stepwise 
decreases in current resulting from addition of increasing concentrations of zinc (1-300 nM). (B) 
Zinc inhibition curves showing the current measured at each concentration of zinc (IZn) divided by 
the current measured with glutamate application alone (IGlu). Inset shows the IC50 for each 
treatment, which indicates the concentration of zinc that reduces NMDAR current in half. The 
IC50s for vehicle (black), scN2AZ (blue), and N2AZ (red) treated cells (3 µM, ≥ 1 hour prior to 
recording) are not different from one another (one-way ANOVA, p = 0.4996, n = 5). Error bars 





2.3.5 Postsynaptic intracellular zinc is necessary for synaptic zinc inhibition of NMDARs 
The simplest model to explain our results thus far is that the ZnT1-GluN2A interaction is 
necessary for zinc inhibition by transporting zinc from the cytoplasm of the postsynaptic cell to 
the extracellular space and in close proximity to the NMDAR. This model predicts that 
postsynaptic intracellular zinc contributes to synaptic zinc inhibition of NMDARs. Because ZX1 
is cell-impermeant, we opted to selectively chelate intracellular zinc by including ZX1 in the 
recording pipette to test the contribution of intracellular zinc to synaptic zinc inhibition of 
NMDARs. ZX1 (100 µM) in the recording pipette was allowed to diffuse into the patched cell for 
at least 30 minutes prior to applying extracellular ZX1. We observed that intracellular ZX1 blocked 
extracellular ZX1 potentiation of NMDAR ESPCs (Figure 14A,B, 5.23 ± 4.22%, n=6, p = 0.64, 
paired t-test of responses before and after ZX1), in contrast to control experiments (no ZX1 in the 
recording pipette), which showed robust potentiation of NMDAR EPSCs (Figure 14A,B: 32.10 ± 
6.36%, n=6, p = 0.009, paired t-test of responses before and after ZX1; Figure 14C: intracellular 
ZX1 versus control, p = 0.006, unpaired t-test). This result indicates that intracellular postsynaptic 
zinc is required for synaptic zinc inhibition of NMDARs.   
 
We next examined whether the well-established routes of entry for zinc into neurons, 
including calcium-permeable AMPAR (Weiss et al., 1993), and L-type calcium channels 
(Kerchner et al., 2000b), mediate potential translocation of synaptic zinc into the cytoplasm of 
cartwheel cells. AMPAR were immediately ruled out by the fact that all our experiments were 
performed in the presence of DNQX. As prior reports have shown that L-type calcium channels 
can also bind to ZnT1 (Levy et al., 2009; Shusterman et al., 2017), we examined whether these 
channels contribute to synaptic zinc inhibition of NMDARs. We applied nimodipine (20 µM) for 
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at least 20 minutes prior to recordings, to inhibit L-type calcium channels and measured zinc 
inhibition of NMDAR responses. We observed no significant differences in ZX1 potentiation of 
NMDAR EPSCs between nimodipine-treated slices (Figure 14D-F, 23.6 ± 6.9%, n = 4) and 
vehicle-treated (DMSO) slices (23.6 ± 9.4% n = 6, unpaired t-test, p = 0.997), indicating that L-










Figure 14 Chelating intracellular zinc reduces zinc inhibition of NMDAR EPSCs 
Legend for Figure 14: (A) Sample NMDAR EPSCs at +40 mV, average of 5 sweeps, in 
response to five pulses at 20Hz stimulation frequency, before and after application of extracellular 
ZX1 (100 µM) in control (no intracellular ZX1) and in 100 µM intracellular ZX1. (B) Time course 
of NMDAR EPSCs normalized to a 5-minute baseline in control (black) and intracellular ZX1 
(green) showing the effect of ZX1 on NMDAR EPSCs. Dotted line marks 100% of baseline. (C) 
Group data show that intracellular ZX1 significantly reduced extracellular ZX1 potentiation of 
NMDAR EPSCs compared to control (unpaired t-test, p = 0.049, n = 4 (control), 8 (intracellular 
ZX1)). Bar graphs represent the average potentiation of responses 15-20 minutes after ZX1 
application. (D) Sample traces of NMDAR EPSCs at +40 mV, average of 5 sweeps, in response 
to five pulses at 20Hz stimulation frequency, before and after application of extracellular ZX1 
(100 µM) in control (0.01% DMSO) and nimodipine (20 µM nimodipine in 0.01% DMSO, ≥ 20 
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minutes prior to beginning of recordings. (E) Time course of NMDAR EPSCs normalized to 5-
minutes baseline in control (black) and extracellular nimodipine (orange) prior before and after 
ZX1 application (black bar, above). Dotted line marks 100% of baseline. (F) Group data show 
ZX1 potentiation was not significantly different between nimodipine and control (unpaired t-test, 
p = 0.99, n = 6 (control), 4 (nimodipine)). Bar graphs represent the average potentiation of 
responses 10-15 minutes after ZX1 application. Error bars indicate mean ± SEM. 
 
2.4 Discussion 
Current models suggest that zinc inhibition of synaptic NMDARs depends exclusively on 
presynaptically-released zinc. In contrast, our results indicate that zinc inhibition of NMDAR 
EPSCs also requires postsynaptic zinc and the presence of GluN2A-ZnT1 association. Our results 
demonstrate that the physical dissociation of GluN2A and ZnT1 by the newly developed peptide 
N2AZ diminished the inhibitory actions of synaptic zinc on NMDAR EPSCs. Moreover, chelation 
of postsynaptic intracellular zinc abolished zinc inhibition of NMDARs. Prior to the work 
presented here, it had been generally assumed that zinc cleft concentrations following its synaptic 
release are sufficient to directly inhibit NMDAR function (Vogt et al., 2000; Pan et al., 2011; 
Vergnano et al., 2014; Anderson et al., 2015; McAllister & Dyck, 2017), without involvement of 
the transport pathway uncovered by our work. However, here we show that ZnT1-GluN2A 
association is necessary for zinc to be rapidly localized to physiologically relevant microdomains 
in very close proximity to the GluN2A-containing NMDARs. Indeed, this is highly reminiscent of 
calcium microdomains that have been postulated for a number of synaptic functions, including 
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rapid synaptic release of neurotransmitters (Berridge, 2006). Whether similar transport processes 
are in place for synaptic zinc to activate or modify other known postsynaptic targets for the metal, 
including the metabotropic zinc receptor GPR39 (Besser et al., 2009) or AMPAR-mediated 
synaptic currents (Kalappa et al., 2015), remains to be determined. 
 
Why is such an indirect signaling path necessary for synaptic zinc inhibition of NMDARs? 
This may be the result of the complex nature of zinc as a signaling molecule itself (Kay & Toth, 
2008; Paoletti et al., 2009; Pan et al., 2011). As alluded to earlier, zinc is a promiscuous ligand 
that acts on a variety of postsynaptic targets (Hershfinkel et al., 2001; Ruiz et al., 2004; Perez-
Rosello et al., 2013; Kalappa et al., 2015; Perez-Rosello et al., 2015). Moreover, not all vesicles 
at zinc-rich synaptic terminals contain zinc (Wenzel et al., 1997; Lavoie et al., 2011), and zinc-
containing vesicle release probability can change with varying levels of activity (Quinta-Ferreira 
& Matias, 2005; Lavoie et al., 2011). Therefore, maintaining adequate signaling requires precise 
spatial zinc regulation, in addition to presynaptic release. The interaction between ZnT1 and 
GluN2A may be reflective of a system that harnesses and directs zinc’s signaling properties, while 
supplying and maintaining specificity of action for a given activity level. As NMDAR function is 
regulated by subunit composition (Cull-Candy & Leszkiewicz, 2004), as well as by its localization 
in postsynaptic structures (Parsons & Raymond, 2014), ZnT1 may endow the zinc-containing 
synapse with a dynamic form of regulation specific for GluN2A-containing NMDAR signals. 
 
ZnT1 expression is also tightly coupled to fluctuations in free intracellular zinc levels 
(Nishito & Kambe, 2019). Rises in intracellular zinc concentrations are quickly detected by the 
metal regulatory element (MRE) transcription factor 1 (MTF1) (Zhao et al., 2014) to induce 
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upregulation of MRE-driven genes, including ZnT1 (Hardyman et al., 2016). As increases in 
intracellular zinc levels have been prominently detected following neuronal depolarization (Li et 
al., 2001; Sheline et al., 2002), it is also conceivable that the ZnT1-GluN2A complex is a key 
component of activity-dependent synaptic processes, perhaps even in synapses that do not express 
ZnT3, and thereby, vesicular zinc. In fact, robust NMDAR activation can lead to intracellular zinc 
liberation from metal binding proteins such as metallothionein (Aizenman et al., 2000) 
independent of synaptic zinc (Vander Jagt et al., 2009), likely as a consequence of glutamate-
stimulated production of oxygen-derived reactive species (Reynolds & Hastings, 1995). We 
suggest that the observed actions of N2AZ on ZnT3-independent zinc inhibition of NMDAR-
mediated responses (i.e. caged glutamate responses in cortical neurons in culture and 100 Hz 
stimulation of parallel fibers, Figures 7 and 8E-G), may be reflective of increases of intracellular 
zinc in response to robust NMDAR activation produced under our experimental conditions. 
Interestingly, manipulations that enhance or diminish ZnT1 expression in cultured neurons have 
yielded subsequent increases or decreases in dendritic spine length, respectively (Mellone et al., 
2015). As NMDAR activation is a significant regulator of synaptic strength and spine dynamics 
(Segal, 2005; Sala & Segal, 2014), ZnT1-mediated zinc inhibition may provide unique forms of 
synaptic plasticity through its regulation of NMDAR function.  
 
One remaining question not successfully addressed in our study is how presynaptic release 
of zinc and postsynaptic transport of intracellular zinc by ZnT1 cooperate to regulate NMDARs. 
It is tempting to assume that the source of the intracellular pool of zinc necessary for NMDAR 
block is derived from the synaptically released pool, translocating to the postsynaptic neuron. 
However, the predominant routes of entry for zinc (LTCC and AMPARs) do not appear to 
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contribute to zinc inhibition of NMDAR inhibition. SLC39A (ZIP) transporters, which move zinc 
into the cytoplasm, may serve as the route for synaptic zinc translocation, and both ZIP1 and ZIP3 
have been previously observed to influence synaptic uptake of zinc, albeit under injurious 
conditions (Qian et al., 2011). However, further experiments will be necessary to fully assess the 
complex interplay between ZnT3 and ZnT1 to regulate zinc’s actions at the NMDAR.  
 
In summary, we developed a cell-permeant peptide that dissociates the zinc transporter 
ZnT1 from the highly zinc sensitive NMDAR subunit GluN2A. This novel tool allowed us to 
uncover the mechanism via which zinc inhibits NMDAR function, which involves not only 
extracellular ZnT3-dependent zinc but also intracellular zinc and ZnT1-GluN2A complexes. We 
propose that the ZnT1-GluN2A association allows the synapse to direct zinc to its high affinity 
binding site within the GluN2A-containing NMDAR by creating a physiologically- and spatially-
distinct extracellular zinc microdomain in the synapse. 
2.5 Materials and Methods 
2.5.1 Experimental Design and materials 
All animal procedures used in experiments were approved by the Institutional Animal Care 
and Use Committee of the University of Pittsburgh School of Medicine. Experiments in dorsal 
cochlear nucleus slices were performed blind to the treatment. Experiments using ZnT3 knockout 
and wildtype animals were performed blind to the genotype of the animal.  All key materials 
utilized are summarized below (Table 1).   
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Table 1 Key Resources 
Reagent type (species) 
or resource 
Designation Source or reference Identifiers 
antibody Mouse anti-GluN2A Sigma Cat #: SAB5200888 
antibody Chicken anti-Map2 Abcam Cat #: ab5392 
antibody Rabbit anti-ZnT1 Alomone Labs Cat #: AZT-011 
antibody goat anti-Flag  Sigma Cat #: F1804 
antibody goat anti-mouse  Thermo Fisher Scientific Cat #: SA5-10176 
commercial assay or kit 
Invitrogen PureLink 
RNA Mini Kit  
Thermo Fisher Scientific Cat #: 12183018A 
commercial assay or kit 
iScript Select cDNA 
Synthesis kit  
BioRad Cat #: 1708896 
commercial assay or kit 
iTaq Universal SYBR 
Green  
BioRad Cat #: 1725120 
commercial assay or kit 
Duolink® In Situ Orange 
Starter Kit Mouse/Rabbit 
Sigma Cat #: DUO92102 
chemical compound, drug Chelex 100 Resin BioRad Cat #: 1422822 
chemical compound, drug TTX Alomone Labs Cat #: T-550 
chemical compound, drug FuGENE 6  Promega Cat #: E2691 
chemical compound, drug DNQX Hello Bio Cat #: HB0261 
chemical compound, drug QX-314 Tocris Biosciences Cat #: 2313 
chemical compound, drug SR95531 Hello Bio Cat #: HB0901 
chemical compound, drug Strychnine  Abcam Cat #: ab120416 
chemical compound, drug ZX1 Strem Chemicals Cat #: 07-0350 
chemical compound, drug MNI-caged glutamate Tocris Biosciences Cat #: 1490 
chemical compound, drug FluoZin-3 Thermo Fisher Scientific Cat #: F24195 
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2.5.2 Neuronal Cultures 
Cortical cultures were prepared from embryonic day 16 rats.  Briefly, pregnant rats 
(Charles River Laboratory) were sacrificed via CO2 inhalation. Embryonic cortices were 
dissociated with trypsin and plated at 670,000 cells per well on glass coverslips in six-well plates. 
Non-neuronal cell proliferation was inhibited after 2 weeks in culture with cytosine arabinoside 
(1–2 μM). Cultures were utilized at 3–4 weeks in vitro for PLA and electrophysiology experiments. 
 
2.5.3 Cell line culture and transfection 
Human embryonic kidney tsa201 cells were maintained in DMEM supplemented with 10% 
fetal bovine serum, 1% GlutaMAX. Cells were plated in 35 mm petri dishes with three 15 mm 
glass coverslips treated with poly D-lysine (0.1 mg/ml) and rat-tail collagen (0.1 mg/ml) at a 
density of 1 x 105 cells/dish. Eighteen to 30 hours after plating, the cells were co-transfected using 
FuGENE 6 Transfection Reagent with cDNA coding for enhanced green fluorescent protein 
(eGFP) for identification of transfected cells and the WT rat NMDAR subunits GluN1-1a (GluN1; 
GenBank X63255) and GluN2A (GenBank M91561 in pcDNA1). GluN1-1a and eGFP were 
expressed using a specialized pCl-neo vector with cDNA encoding eGFP inserted between the 
CMV promoter and the GluN1 open reading frame to express eGFP and GluN1 as separate 
proteins. At the time of transfection, 200 μM dl-APV was added to culture medium to prevent 
NMDAR-mediated cell death. For experiments testing the effect of N2AZ and scN2AZ, cells were 
incubated with 3 μM peptide for at least 1 hr prior to recording. 
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2.5.4 Proximity ligation assay 
Proximity ligation assays were performed using Duolink PLA kit. Cortical cultures (3–4 
weeks in vitro) were treated overnight with either N2AZ or scN2AZ (3 µM, dissolved in water). 
Coverslips were fixed in ice cold methanol for 5 minutes, rinsed in phosphate buffered saline (PBS) 
then permeabilized with 0.1% Triton-X in PBS. Coverslips were then incubated with primary 
antibodies: rabbit anti-ZnT1, mouse anti-GluN2A, and chicken anti-MAP2. Coverslips were 
incubated with a donkey anti-chicken fluorescent secondary antibody targeting MAP2 antibodies 
to visualize neuron morphology. The PLA reaction was then completed according to DuoLink 
PLA protocol. Briefly, coverslips were incubated in DuoLink secondary antibodies (anti-rabbit 
and anti-mouse) which are conjugated with complementary oligonucleotides. Ligation solution 
was added to hybridize connector oligonucleotides and PLA probes, allowing the oligonucleotides 
to join in a closed loop when secondary antibodies were in close proximity. Next, the reaction was 
amplified with rolling-circle amplification (RCA) using the closed loop hybridized probes as a 
template. PLA probes were fluorescently labeled with oligonucleotides which hybridized to the 
RCA product during amplification. Coverslips from sister cultures were treated with either 
scN2AZ or N2AZ and reactions were run simultaneously using the same preparation of reagents. 
Coverslips were mounted on glass slides using DuoLink mounting media and 4 random fields of 
view were imaged from each coverslip using a 60x oil objective on a Nikon A1R laser scanning 
confocal. PLA puncta were counted automatically with Fiji ImageJ (Version 2.0) software. We 
used maximum intensity projection of 8 sequential images in the z plane. All images were 
normalized to the same intensity threshold using the Yen threshold setting prior to automated 
quantification of puncta.  
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2.5.5 Brain Slices 
Male and female mice (postpartum days 18-28) were anesthetized with isoflurane and 
sacrificed. Brains were rapidly dissected and sectioned with a vibratome (Leica, VT1000S) into 
210 µm thick coronal slices of the brainstem containing dorsal cochlear nucleus (DCN). Slices 
were incubated in ACSF containing (in mM) NaCl 130, KCl 3, CaCl2 2.4, MgCl2 1.3, NaHCO3 
20, HEPES 3, and glucose 10, saturated with 95% O2/5% CO2 (vol/vol), pH ∼7.3, ∼300 mOsm at 
35 °C for 1 h before being moved to room temperature. During preparation, ACSF was treated 
with Chelex 100 resin to remove any contaminating zinc. After applying Chelex to the ACSF, 
high-purity calcium and magnesium salts were added (99.995% purity). All plastic and glassware 
were washed with 5% high-purity nitric acid.  
 
2.5.6 Electrophysiology 
Whole-cell voltage-clamp recordings from tsa201 cells were performed 18-30 hours after 
transfection. Pipettes were fabricated from borosilicate capillary tubing (OD = 1.5 mm, ID = 0.86) 
using a Flaming Brown P-97 electrode puller (Sutter Instruments) and fire-polished to a resistance 
of 2.5 – 4.5 MΩ with an in-house fabricated microforge. Intracellular pipette solutions consisted 
of (in mM): 130 CsCl, 10 HEPES, 10 BAPTA, and 4 MgATP with pH balanced to 7.2 ± 0.05 using 
CsOH and final osmolality of 280 ± 10 mOsm. Extracellular recording solution contained (in mM): 
140 NaCl, 2.8 KCl, 1 CaCl2, 10 HEPES, 10 tricine, and 0.1 glycine and was balanced to pH 7.2 ± 
0.05 and osmolality 290 ± 10 mOsm with NaOH and sucrose, respectively. Glutamate (Glu), and 
ZnCl2 were diluted from concentrated stock solutions in extracellular solution each day of 
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experiments. Buffered Zn2+ solutions were prepared as previously described (Paoletti et al., 1997) 
via serial dilution. Extracellular solutions were delivered to the cell using a fast perfusion system. 
Whole-cell currents were recorded using an Axopatch 200A patch-clamp amplifier (Molecular 
Devices), low-pass filtered at 5 kHz, and sampled at 20 kHz in pClamp10.7 (Molecular Devices). 
In all recordings from tsa201 cells, series resistance was compensated 85-90% and an empirically 
determined -6 mV liquid junction potential between the intracellular pipette solution and the 
extracellular recording solution was corrected.  
 
The effect of the N2AZ on Zn2+ inhibition of GluN1/2A receptors was determined using 
the protocol shown in Fig 5I. 1 mM Glu was applied for 30 s until current reached steady-state, 
followed by sequential applications (5 s each) of 1 mM Glu and Zn2+ at 1, 3, 10, 30, 100, and 300 
nM. A final 30 s application of Glu in the absence of Zn2+ was then performed to allow recovery 
from inhibition. Zn2+ IC50 was estimated by fitting the following equation to data: 
𝐼𝑍𝑛
𝐼𝐺𝑙𝑢







where IZn/IGlu was calculated as the mean current over the final 1 s of Zn2+ application 
divided by the average of the mean steady state currents (final 1 s) elicited by Glu before and after 
Zn2+ application. A (IZn/IGlu at saturating Zn2+), IC50, and nH (Hill coefficient) were free parameters 
during fitting. Curve fitting and statistical comparisons were performed in Prism 8. IC50s were 
compared by one-way ANOVA. 
 
Whole-cell recordings from cultured cortical neurons were obtained with glass 
micropipettes (3-6 MΩ) containing (in mM): 140 CsF, 10 CsEGTA, 1 CaCl2, 10 HEPES, pH = 
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7.2, 295 mOsm. Extracellular recording solution contained (in mM): 150 NaCl, 2.8 KCl, 1.0 CaCl2, 
10 HEPES, 10 µM glycine, pH = ~7.2, ~300 mOsm. Using Ephus (Suter et al., 2010)  and a 
Multiclamp 700B amplifier (Molecular Devices), NMDAR EPSCs were recorded in voltage clamp 
(held at -70 mV) in the presence of TTX (300 nM, sodium channel blocker), DNQX (20 µM, 
AMPA and kainate receptor antagonist), and 4-Methoxy-7-nitroindolinyl (MNI)-caged glutamate 
(40 µM). Neurons were visualized by including 10 µM Alexa 594 in the internal solution. To 
evoke NMDAR EPSCs, we photolytically uncaged MNI-caged glutamate onto dendrites at four 
locations 0, 40, 80, and 120 µm from the cell soma using 1 ms pulses of UV-laser light (355 nm, 
DPSS Lasers). The ZX1-mediated potentiation for each cell was calculated as the average percent 
increase in responses following application of the metal chelator across these 4 uncaging locations.  
 
For brain slice recordings, whole-cell recordings of NMDAR EPSCs of DCN cartwheel 
cells were obtained with micropipettes (3-6 MΩ) containing (in mM) 128 Cs(CH3O3S), 4 
MgCl2•6H2O, 4 Na2ATP, 10 HEPES, 0.3 Tris-GTP, 10 Tris-phosphocreatine, 1 CsEGTA, 1 QX-
314, 3 sodium ascorbate, pH = ~7.2, 300 mOsm in chelexed ACSF with the following composition: 
(in mM) NaCl 130, KCl 3, CaCl2 2.4, MgCl2 1.3, NaHCO3 20, HEPES 3, and glucose 10, saturated 
with 95% O2/5% CO2 (vol/vol), pH ∼7.3, ∼300 mOsm. Cartwheel cells were identified by the 
presence of complex spikes (Tzounopoulos et al., 2004) in cell-attached configuration before 
break-in or in response to current injections in current-clamp mode immediately after break-in. 
NMDAR EPSCs were recorded in voltage clamp mode, at a holding potential of +40 mV, in the 
presence of DNQX (20 μM), SR95531 (20 μM, GABAAR antagonist), and strychnine (1 μM, GlyR 
antagonist). ZX1 (100 µM) was included in the pipette in experiments where noted. Whole-cell 
recordings of AMPAR EPSCs were obtained with micropipettes containing (in mM) 113 K-
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gluconate, 4.5 MgCl2•6 H2O, 14 Tris-phosphocreatine, 9 HEPES, 0.1 EGTA, 4 Na2ATP, 0,3 Tris-
GTP, 10 sucrose, pH = 7.3, 295 mOsm. AMPAR EPSCs were recorded in voltage clamp mode at 
a holding potential of -70 mV in the presence of SR9551 (20 µM) and strychnine (1 μM). Both 
NMDAR and AMPAR EPSCs were evoked using an Isoflex stimulator (A.M.P.I, 0.1 ms pulses) 
stimulating parallel fibers with voltage pulses through a theta glass electrode. For paired-pulse 
experiments, inter-stimulus interval was 50 ms. Once a stable response was established, ZX1 (100 
µM) was added to the recording solution to measure the effect of zinc chelation on EPSCs. The 
series resistance was not compensated because the currents measured were relatively small, 
therefore there was minimum voltage clamp error. The cell parameters were monitored during the 
recording by delivering −5 mV voltage steps for 50 msec at each sweep. The peak current value 
(ΔIpeak) generated immediately after the step in the command potential was used to calculate series 
resistance (Rseries) using the following formula: Rseries = -5 mv/ ΔIpeak. The difference between 
baseline and steady-state current (ΔIss) was used to calculate input resistance (RI) using the 
following formula: RI = −5 mV/ΔI − Rseries. Recordings were excluded from further analysis if the 
series resistance or input resistance changed by more than 20% compared to the baseline period. 
Data were low-pass-filtered at 4 kHz and sampled at 10 kHz. NMDAR EPSC peak values were 
averaged over a 20-ms time window using custom Matlab 2012a software. All values reported are 
animal-based values, in cases where multiple cells were recorded from the same animal 
preparation, the average of cells is presented.  All recordings were performed at room temperature. 
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2.5.7 Quantitative real-time PCR (qPCR) 
For qPCR analysis of rat cortical cultures, cells were harvested at 5, 12, 19, and 26 DIV 
and RNA was isolated using Invitrogen PureLink RNA Mini Kit. cDNA was synthesized from 
RNA transcripts using iScript Select cDNA Synthesis kit using Eppendorf Thermocycler. qRT-
PCRs were performed on a Bio-Rad CFX qRT-PCR machine using iTaq Universal SYBR Green 
Supermix. Relative expression was calculated using -actin as a reference gene. Custom primers 
against rat -actin (Forward: TTCAACACCCCAGCCATGT Reverse: 
GCATACAGGGACAACACAGCC; Invitrogen) and rat ZnT1 (Forward: 
TGGGCGCTGACGCTTACT; Reverse: GTCAGCCGTGGAGTCAATAGC; Invitrogen) were 
designed using NCBI Primer-BLAST. 
 
2.5.8 Zinc efflux assay 
HEK293 cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing: 
100 units/ml penicillin, 0.1 mg/ml streptomycin, 2 mm glutamine, and 10% (v/v) fetal calf serum 
in a 5% CO2 humidified atmosphere at 37 °C. To express ZnT1, HEK 293 cells were transfected 
with ZnT1 or empty plasmid (control) using CaPO4 precipitation. Briefly,1 μg mouse ZnT-1 
(pCMV6; ZnT1 GenBank Q60738) or empty vector plasmid (pCMV6, Origene) were incubated 
with 2 M calcium chloride in HEPES buffered solution containing 1.5 mM Na2HPO4 to generate 
a co-precipitate, this solution was then dispersed onto cultured cells for 6 hours. Twenty-four hours 
later, cells were treated overnight with N2AZ or scN2AZ (3 μM). To visualize intracellular zinc, 
cells were loaded with the fluorescent zinc indicator FluoZin-3 (2 μM) for 25 min at room 
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temperature before imaging. Cells were imaged using 480 nm excitation filter and an emission 525 
nm long pass filter on a Zeiss Axiovert 100 inverted microscope with a Polychrome IV 
monochromator (T.I.L.L. Photonics) and a cooled CCD camera (PCO). To measure zinc efflux, 
cells were superfused with Ringer's solution (composition in mM: NaCl 120, MgCl 0.8, KCl 5.4, 
CaCl 1.8, HEPES 20, glucose 15) and 1 μM Zn2+ with 5 μM pyrithione were added for 150 
seconds. The FluoZin-3 signal was normalized to 10 second baseline in each experiment. Rates of 
initial decrease of the fluorescent signal following removal of Zn2+  pyrithione were determined 
during a 100 second period. For each experiment, at least 30 cells were imaged per coverslip and 
rates were averaged for 3-5 coverslips performed as 3 independent experiments. Fluorescence 
imaging measurements were acquired using Axon Imaging Workbench 5.2 (INDEC BioSystems) 
and analyzed using Excel and Prism GraphPad. 
 
2.5.9 Peptide spot array and far-Western assay 
Far-Western protein-binding affinity assays were performed as previously described  (Yeh 
et al., 2017). Peptide spot arrays (15-mers) spanning the proximal C-terminus residues 1390–1464 
of mouse GluN2A (Uniprot# P35436) in overlapping 1 residue steps were constructed using the 
Spots-synthesis method. Standard 9-fluorenylmethoxy carbonyl (Fmoc) chemistry was used to 
synthesize the peptides and spot them onto nitrocellulose membranes, which were pre-derivatized 
with a polyethylene glycerol spacer (Intavis). Fmoc protected and activated amino acids were 
spotted in 20–30 arrays on 150 by 100 mm membranes using an Intavis MultiPep robot. The 
nitrocellulose membrane containing the immobilized peptides was soaked in N-cyclohexyl-3-
aminopropanesulfonic acid (CAPS) buffer (10 mM CAPS, pH 11.0, with 20% v/v methanol) for 
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30 min, washed once with Tris-buffered 0.1% Tween 20 (TBST), and then blocked for 1 h at room 
temperature (RT) with gentle shaking in TBST containing 5% (w/v) nonfat milk and then 
incubated with enriched Flag-tagged ZnT1 (SLC30a1) protein overnight at 4°C with gentle 
shaking. Next, the membrane was incubated in primary antibody for Flag for 1 hr at RT with gentle 
shaking, followed by washing with TBST. Finally, the membrane was incubated in secondary 
antibody for 45 min, washed for 3 times 5 min in TBST, and then visualized by infrared 
fluorescence (Li-Cor). Four independent peptide spot arrays were used in this study. A second set 
of membranes (n = 4) was treated as above, but also in the presence of 100 µM of either N2AZ or 
scN2AZ and compared to 0.1% DMSO. For each experiment, an additional peptide array was done 
with omission of Flag-tagged ZnT1 (SLC30a1) protein to measure and correct for the background 
due to the primary and secondary antibodies. 
 
2.5.10 Statistical Analyses 
Slice electrophysiology experiments using N2AZ and scN2AZ were completed blind to the 
identity of the peptide. Experiments in ZnT3 knockout and wild type animals were completed blind 
to the genotype. Electrophysiology recordings in cortical cultures and DCN slices were obtained 
using Ephus (Suter et al., 2010) software run in Matlab 2012a (MathWorks). Cell parameters and 
response peaks were calculated using custom Matlab scripts. For neuronal culture 
electrophysiology, ZX1 potentiation was measured as the percent increase in NMDAR amplitude 
5 minutes after the application of ZX1. In slice experiments, ZX1 potentiation was calculated as 
the average percent increase over baseline of NMDAR or AMPAR EPSCs 10-15 minutes after the 
addition of ZX1 (Figures 8,9,10 & 14D-F) or 15-20 minutes after the addition of ZX1 (Figure 
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14A-C). Un-paired t-tests and ANOVAs were used to compare between treatments or genotypes. 
To determine if ZX1 significantly potentiated responses, paired t-tests were used to compare 
amplitude of peak responses before and after addition of ZX1. Statistical analysis was completed 
in Prism 8 (GraphPad).  
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3.0 Chapter 3: Zinc-dependent Upregulation of ZnT1 Enhances Zinc Inhibition of NMDA 
Receptors 
3.1 Overview 
Zinc is loaded into a subset of glutamate-containing presynaptic vesicles by the transporter 
ZnT3 and is synaptically released in an activity-dependent manner. Zinc modulates 
neurotransmission through its actions on postsynaptic receptors, including high-affinity inhibition 
of NMDA receptors. Recently, an additional postsynaptic mechanism of transport was identified 
that critically regulates endogenous zinc inhibition of NMDARs. In this new model of zinc 
regulation, the postsynaptic transporter ZnT1 mediates zinc inhibition of NMDARs through its 
interaction with the highly zinc-sensitive GluN2A subunit. This positions ZnT1, a transporter 
which moves zinc from the cytoplasm to the extracellular domain, as a direct regulator of 
NMDAR-mediated neurotransmission. ZnT1 expression is transcriptionally driven by the metal-
responsive transcription factor 1 (MTF-1). When MTF-1 binds zinc, it translocates to the nucleus 
and engages metal response elements (MRE) on zinc-regulated genes, including ZnT1, to 
upregulate expression. In this study, we found that increasing intracellular zinc strongly drives the 
MRE/MTF-1 system in cortical neurons in vitro, increases the number of GluN2A-ZnT1 
interactions, and enhances zinc inhibition of NMDARs. Importantly, this effect is absent when the 
interaction between GluN2A and ZnT1 is disrupted by a cell-permeable peptide. Together, these 
results suggest that alterations in intracellular zinc levels can dynamically regulate NMDAR 
transmission by upregulating ZnT1-mediated inhibition.  
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3.2 Introduction 
Zinc is a neuromodulator with diverse roles in synaptic transmission, synaptic plasticity, 
and sensory processing (McAllister & Dyck, 2017). The majority of loosely bound, so-called 
‘labile’ zinc in the brain is found in presynaptic vesicles in a subset of glutamatergic neurons 
throughout the cerebral cortex, hippocampus, amygdala, and auditory brainstem (Cole et al., 
1999). These zinc-containing neurons package zinc into vesicles using the transporter ZnT3 and 
release it in an activity-dependent manner (Palmiter et al., 1996; Anderson et al., 2015). The ion 
acts on multiple postsynaptic receptors to modulate both excitatory (Westbrook & Mayer, 1987; 
Kalappa et al., 2015) and inhibitory (Bloomenthal et al., 1994; Hosie et al., 2003) transmission. 
Notably, zinc inhibits NMDA receptors through an allosteric binding site on the N-terminal 
domain of the GluN2 subunit (Paoletti et al., 2000; Erreger & Traynelis, 2008). GluN2A-
containing NMDARs are the most sensitive receptors and require just nanomolar concentrations 
of the metal for inhibition (Paoletti et al., 1997).  
 
Multiple mechanisms generate transient increases in intracellular zinc, including 
translocation of vesicular zinc into the postsynaptic cell (Li et al., 2001), as well as liberation of 
zinc from intracellular stores (Dineley et al., 2008; Kiedrowski, 2012; Sanford et al., 2019). 
Intracellular zinc influences a variety of signaling pathways, including gene transcription 
(Smirnova et al., 2000), kinase signaling cascades (Murakami et al., 1987; Seo et al., 2001), and 
cell death signaling cascades (Aizenman, 2019). To terminate signaling, zinc must be bound or 
sequestered away from its signaling targets. Indeed, a complex system of zinc transporters and 
metalloproteins work together to regulate the localization and concentration of zinc, including at 
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least twenty four different zinc transporters (Colvin et al., 2000; Colvin et al., 2010).  However, it 
remains unclear how the regulation of zinc in neurons contributes to synaptic function.  
 
Previously it was assumed that presynaptic release and diffusion across the cleft was 
sufficient to explain the modulatory actions of zinc (Vergnano et al., 2014). However, recent work 
revealed an additional postsynaptic mechanism where the transporter ZnT1 is necessary for 
NMDARs inhibition (Krall et al., 2020). ZnT1, which transports zinc from the cytoplasm to the 
extracellular space, binds directly to the GluN2A subunit of NMDARs (Mellone et al., 2015). 
Disrupting this interaction between GluN2A and ZnT1 blocks endogenous zinc inhibition of 
NMDARs. Furthermore, chelating intracellular zinc, thus removing ZnT1’s source, is also 
sufficient to prevent zinc inhibition of NMDARs (Krall et al., 2020). Therefore, ZnT1 critically 
regulates the localization and concentration of zinc to drive endogenous NMDAR inhibition. This 
reveals that regulation of zinc in the synapse is more complex than previously assumed. 
 
ZnT1 expression levels are not static, but instead dynamically respond to intracellular zinc 
state through transcriptional regulation. When intracellular zinc increases, it binds to the metal 
regulatory transcription factor 1 (MTF-1) (Dalton et al., 1997). MTF-1 rapidly translocates to the 
nucleus where it binds to metal response elements (MRE) on target genes to regulate transcription 
(Westin & Schaffner, 1988; Smirnova et al., 2000). The ZnT1 gene, SLC30A1, contains two MRE 
tandem sequences in its promotor region, such that ZnT1 is rapidly upregulated following MTF-1 
activation (Langmade et al., 2000).  This zinc-induced upregulation of ZnT1 protects cells against 
zinc toxicity (Palmiter, 2004), suggesting that the MRE/MTF-1 system functionally increases zinc 
efflux in response to the zinc state. Given that ZnT1 also regulates zinc inhibition of NMDARs, 
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MTF-1 driven upregulation may be a novel mechanism regulating NMDAR-mediated 
neurotransmission. Here, we test the hypothesis that zinc-induced upregulation of ZnT1 enhances 
inhibition of NMDARs via its interaction with GluN2A.   
3.3 Results 
3.3.1 Zinc Pyrithione drives MRE-regulated expression 
The aim of this study was to examine if ZnT1-mediated inhibition of NMDARs 
dynamically changes in response to cellular zinc state. Therefore, we first needed to identify a 
treatment to sufficiently increase zinc to activate MTF-1 without itself causing neuronal injury 
(Choi et al., 1988). To rapidly increase intracellular zinc, we utilized the zinc ionophore pyrithione. 
This allowed for the use of lower, sub-lethal concentrations of zinc (10 µM) because it circumvents 
use of endogenous transport systems or ion channels for entry into the cell, thus reducing off target 
signaling that could be triggered by higher concentrations of zinc (Sensi et al., 1997). 
  
To determine if ZnPyr treatment is sufficient to activate MTF-1 driven gene expression, 
we used a MRE-luciferase assay, as described previously (Hara & Aizenman, 2004). In this assay, 
neurons are transfected with a plasmid encoding a firefly luciferase with an MRE sequence in the 
promoter. Firefly luciferase activity is then assayed and serves as a measure of MRE-driven gene 
upregulation. As a control for transfection efficacy, a non-inducible Renilla luciferase is also 
transfected and assayed. One day after transfection, neurons were treated with pyrithione (250 nM, 
Pyr) alone or in conjunction with zinc (10 µM, ZnPyr) overnight. Zinc-induced gene expression 
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was quantified by measuring both Renilla and firefly luciferase activity and taking the ratio of 
Firefly/Renilla activity. We observed that ZnPyr led to a significant increase in MRE-driven 
transcription and subsequent Firefly/Renilla luciferase activity (6.41 ± 0.90, n = 5) compared to 
Pyr (2.7 ± 0.18, n = 3;)  and untreated controls (3.77 ± 0.29, n = 12) (Figure 15, One-way ANOVA: 
p = 0.0012, Sidak multiple comparisons: Control versus Pyr, p = 0.5; Control versus ZnPyr, p = 
0.003; Pyr versus ZnPyr, p = 0.004).  A significant level of MRE-driven luciferase expression was 
observed with this treatment protocol with no observable damage to the cells, therefore this 











Figure 15 ZnPyr treatment induces MRE-drive gene transcription 
Legend for Figure 15: (A) Schematic of the luciferase assay showing binding of zinc to MTF1 and 
subsequent upregulation of firefly luciferase. (B)The average ratio of MRE-driven firefly 
luciferase activity to Renilla luciferase activity for untreated, Pyr (250 nM), or ZnPyr (10 µM 
ZnCl2, 250 nM Pyr) treated neurons (One-way ANOVA, p = 0.0012; Control, n =12; Pyr, n = 3; 
ZnPyr,  n =5). ZnPyr treatment led to a significant increase in firefly/Renilla activity compared to 
control (Sidak multiple comparisons, p = 0.004) and Pyr (p = 0.003) No significant increase was 
observed with Pyr treatment compared to control (p = 0.5). Error bars indicate mean ± SEM. 
3.3.2 ZnT1-GluN2A interactions are upregulated with increased intracellular zinc 
Next we aimed to determine if intracellular zinc and MRE-driven gene expression leads to 
an upregulation of GluN2A-ZnT1 interactions in neurons. To accomplish this, we used a proximity 
ligation assay that fluorescently labels locations where GluN2A and ZnT1 are within 40 nm of 
each other (Krall et al., 2020). Neurons were treated overnight either with ZnPyr (10 µM ZnCl2, 
250 nM Pyr) to increase intracellular zinc levels or Pyr alone as a control. We hypothesized that 
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ZnPyr would increase the number of PLA puncta by increasing the instances GluN2A-ZnT1 
interactions. Alternatively, ZnPyr treatment could simply increase the likelihood of ZnT1 being in 
the proximity of GluN2A, with no change in its direct interaction with GluN2A. To distinguish 
between these two possibilities, neurons were treated overnight with a cell-permeant peptide that 
specifically disrupts GluN2A-ZnT1 interaction (N2AZ, 3 µM) or its scramble control (scN2AZ, 3 
µM) (Krall et al., 2020).   
 
We found that in scN2AZ treated cells, ZnPyr led to an average 2.4-fold increase in PLA 
puncta compared to sister coverslips treated with Pyr (Figure 16A,C; 2.4 ± 0.23 ZnPyr puncta/Pyr 
puncta; n=4), suggesting that zinc upregulates ZnT1-GluN2A interactions. N2AZ treated cells 
exhibited no increase with ZnPyr treatment compared to Pyr control (Figure 16B,C; 0.986 ± 0.33 
ZnPyr puncta/Pyr puncta ; n=3). The zinc-induced increase in PLA puncta was significantly 
different between N2AZ and scN2AZ treated neurons (Figure 16C, Unpaired t-test, p = 0.017). 
This indicates that zinc treatment upregulates the number of GluN2A-ZnT1 interactions in 
neurons. This upregulation is blocked by specific disruption of GluN2A-ZnT1 by N2AZ, 




Figure 16 ZnPyr increases GluN2A-ZnT1 interactions in scN2AZ but not N2AZ treated neurons 
Legend for Figure 16: Representative images of rat cortical cultures following proximity ligation 
assay (PLA) of GluN2A and ZnT1 in scN2AZ (A) and N2AZ (B) treated cultures, comparing Pyr 
(left column) to ZnPyr (right column) treated cells. Top row shows MAP2 immunofluorescently 
labeled in white to visualize neuron morphology. Middle row shows the PLA sites of interaction 
between GluN2A and ZnT1 (red puncta). Bottom row shows the merged images. (C) 
Quantification of the average ratio of ZnPyr to Pyr PLA puncta counts in scN2AZ (blue) and 
N2AZ (red) treated neurons. scN2AZ treated neurons exhibited a significantly higher ratio 
compared to N2AZ (unpaired t-test, p = 0.017, n = 4,3). Error bars indicate mean ± SEM. 
 
3.3.3 Increasing intracellular zinc leads to enhanced ZnT1-mediated zinc inhibition of 
NMDARs 
Previously, we showed that the interaction between GluN2A and ZnT1 is critical for 
endogenous zinc inhibition of NMDAR currents in cortical cultures (Krall et al., 2020). We 
therefore hypothesized that upregulating the GluN2A-ZnT1 interaction would increase zinc 
inhibition of NMDARs. To test this, we used whole-cell recording of cultured neurons under 
voltage clamp, held at -70 mV in magnesium-free conditions, and evoked NMDAR responses by 
photolytically uncaging glutamate onto the cell. Similar to PLA experiments, neurons were 
previously treated overnight with either Pyr or ZnPyr, in the presence of scN2AZ or N2AZ to 
determine if increasing intracellular zinc increases ZnT1-dependent zinc inhibition of NMDARs. 
Zinc inhibition was determined by measuring the potentiation of NMDAR responses after the 
addition of the high affinity zinc chelator, ZX1 (100 µM). We found that in scN2AZ treated 
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neurons, ZnPyr led to a significant increase in ZX1-dependent NMDAR potentiation compared to 
Pyr controls (Figure 17A, Pyr: 14.65 ± 6.90 %; ZnPyr: 40.37 ± 9.04%, unpaired t-test, p = 0.04; n 
= 8). In contrast, NMDAR-mediated currents in N2AZ treated cells did not appear to potentiate 
following ZX1 treatment and there were no significant differences between Pyr and ZnPyr treated 
groups. (Figure 17C, Pyr: -3.12  ± 3.54 %; ZnPyr: 1.69 ± 10.00 %, unpaired t-test, p = 0.68, n = 
7). Together, these data suggest that increasing intracellular zinc with ZnPyr upregulates ZnT1-
mediated zinc inhibition of NMDARs.  
 
 
Figure 17 ZnPyr increases ZnT1-dependent zinc inhibition of NMDARs 
Legend for Figure 17: (A,C) ZX1 potentiation of NMDAR currents was significantly increased 
between ZnPyr and Pyr groups in scN2AZ treated neurons (A, unpaired t-test, p = 0.04, n = 8). 
However, no significant differences were seen in N2AZ treated neurons (C, unpaired t-test, p = 
.068, n =7). Bar graphs represent the average potentiation of responses 10 minutes after ZX1 
application. Error bars indicate mean ± SEM. (B,D) Sample traces of NMDAR currents from 
scN2AZ (B) and N2AZ (D) treated groups, averaged over 10 sweeps, evoked by photolysis of 
MNI-caged glutamate in cultured cortical neurons held at -70 mV in Mg2+ free solution, before 
(blue, scN2AZ; red, N2AZ, 3 µM) and after application of ZX1 (black; 100 µM).  
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3.4 Discussion 
A growing body of literature is uncovering the diverse roles of zinc as a dynamic signaling 
ion with a complex system of regulation (McAllister & Dyck, 2017). In this study, we found a 
novel role of zinc-regulated gene expression, in which intracellular zinc enhances inhibition of 
NMDARs via increased interactions between the zinc transporter ZnT1 and the GluN2A subunit. 
This suggests that ZnT1’s regulation of glutamatergic transmission can be strongly influenced by 
changes in intracellular zinc concentrations. Previous studies have shown that increases in 
intracellular zinc can drive ZnT1 expression to protect against zinc toxicity (Palmiter, 2004), 
consistent with its documented role for maintenance of zinc homeostasis (Palmiter & Findley, 
1995). This study expands on the role of zinc-dependent regulation of ZnT1 to reveal an additional 
influence on NMDAR-mediated transmission. Glutamate, in addition to activating NMDARs, has 
been associated with postsynaptic increases in intracellular zinc (Dineley et al., 2008). Therefore, 
intracellular zinc may act as a signal to increase NMDAR inhibition following activation through 
upregulation of ZnT1-mediated zinc transport.  
 
Although this study used exogenous zinc to alter intracellular levels, multiple endogenous 
mechanisms increase postsynaptic zinc, as mentioned above. Chemical stimulation with either 
glutamate or KCl generates postsynaptic zinc transients in neurons (Dineley et al., 2008; Ha et al., 
2018; Sanford et al., 2019; Sanford & Palmer, 2020). These may occur either through uptake of 
synaptically released zinc or liberation of the ion from intracellular stores. Multiple channels 
conduct zinc into the cell, including calcium permeable AMPA receptors (Jia et al., 2002), 
NMDARs (Koh & Choi, 1994; Marin et al., 2000), L-type calcium channels (Kerchner et al., 
2000a), and TRP channels (Hu et al., 2009; Inoue et al., 2010). Zinc influx has been linked to zinc 
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toxicity in multiple pathological conditions including seizures (Frederickson et al., 1989), 
ischemia (Koh et al., 1996) and traumatic brain injury (Suh et al., 2000), and, as such, the 
mechanism uncovered here may be a protective mechanism to minimize cell injury.   
 
In addition to zinc influx, multiple studies have found that zinc transients are induced by 
neuronal stimulation even in the presence of extracellular zinc chelators, suggesting an 
intracellular origin (Dineley et al., 2008; Sanford & Palmer, 2020). These transient can result from 
acidification driven by NMDAR-mediated calcium influxes and subsequent proton-dependent 
release of zinc from intracellular ligands. (Kiedrowski, 2012; 2014) Similarly intracellular zinc 
may arise from NMDAR-dependent generation of reactive oxygen species triggering zinc release 
from metallothioneins (Reynolds & Hastings, 1995; Aizenman et al., 2000). Interestingly, zinc has 
also been shown to be released from thapsigargin-sensitive stores in an IP3 dependent manner, 
suggesting the Gq-coupled metabotropic receptors such as Type 1 mGluRs or mZnR, can trigger 
intracellular zinc transients  (Stork & Li, 2010). Together this shows multiple convergent 
mechanisms can mediate increases in intracellular zinc in response to physiological or 
pathophysiological neuronal activity. 
 
Although the full consequences of changes in postsynaptic intracellular zinc is not yet fully 
understood, a variety of synaptic functions have been identified that are modulated by zinc. Zinc 
transients induced by neuronal depolarization triggers differential expression of 931 genes, 
including those implicated in synaptic structure and transmission (Sanford et al., 2019). 
Interestingly this change in transcription occurs when intracellular zinc levels increase to just 220 
pM, suggesting that even modest concentrations of zinc can have broad influence on neurons 
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(Sanford et al., 2019). Intracellular zinc also influences synaptic plasticity, including modulation 
of long-term potentiation at both CA1 and CA3 neurons in the hippocampus (Takeda et al., 2015; 
Tamano et al., 2017). The latter is mediated by activation of the TrkB receptor via zinc-dependent 
activation of Src family kinase activity (Huang et al., 2008). Intracellular zinc has also been linked 
to structural organization and remodeling of the synapse. Notably, zinc stabilizes Shank2 and 3, 
postsynaptic density scaffolding proteins critical for synapse maturation and plasticity (Arons et 
al., 2016; Ha et al., 2018). Postsynaptic zinc treatment alters AMPAR composition at the synapse 
via a Shank-dependent recruitment of GluA2-containing receptors to the surface (Ha et al., 2018). 
ZnT1 expression also influences synaptic morphology. Overexpression or knockdown of the 
transporter causes increase or decrease in dendritic spine length and width respectively (Mellone 
et al., 2015). Although the mechanism of ZnT1-driven alteration in morphology are unknown, 
NMDAR activation is known to be a critical modulator of synaptic strength and morphology (Sala 
& Segal, 2014). Therefore, ZnT1 may mediate morphological changes through its regulation of 
NMDAR activation. However, further studies are needed to uncover how zinc-dependent 
regulation of ZnT1 contributes to downstream NMDAR signaling and subsequent synaptic 
remodeling. Together these various zinc-dependent signaling cascades point to the multifaceted 
impact of zinc, both intracellularly and extracellularly, as a regulator of synaptic function.  
 
Beyond its role in zinc homeostasis, ZnT1 is associated with a variety of signaling 
functions. In addition to regulating inhibition of NMDARs, ZnT1 regulates Ras/Raf/MEK/ERK 
signaling (Jirakulaporn & Muslin, 2004) and voltage gated calcium channels (Levy et al., 2009; 
Shusterman et al., 2017). ZnT1 interacts directly with the N-terminal regulatory domain of Raf-1 
to promote its activity. ZnT1 enhancement of Ras-ERK signaling leads to upregulation of T-type 
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calcium channel expression on the plasma membrane and subsequent increase in calcium currents 
(Mor et al., 2012). ZnT1 also binds directly to L-type calcium channels to inhibit their activity 
(Levy et al., 2009; Shusterman et al., 2017). Therefore, alterations in ZnT1 may influence multiple 
signaling pathways beyond zinc inhibition of NMDARs. Finally, decreases in intracellular zinc 
levels reduce ZnT1 expression through endocytosis and degradation of the transporter (Nishito & 
Kambe, 2019), allowing for bidirectional regulation of ZnT1-mediated signaling. Together, this 
suggests that the intracellular zinc state may be a critical regulator of signaling pathways, including 
NMDAR activation, through its impact on ZnT1. 
 
In summary, we determined that intracellular zinc upregulates NMDAR inhibition through 
the zinc transporter ZnT1. Furthermore, this zinc-dependent regulation depends on the association 
between the GluN2A subunit of NMDARs and ZnT1. Together these results reveal a novel 
mechanism by which intracellular zinc influences NMDAR signaling in which intracellular zinc 





Figure 18 Proposed model of zinc-induced upregulation of ZnT1-mediated NMDAR inhibition 
Legend for Figure 18: Increases in intracellular zinc bind to MTF-1 to drive MRE-driven gene 
expression. This leads to upregulation of expression of ZnT1, which associates with GluN2A 
subunits in the membrane. Increased GluN2A-ZnT1 interactions subsequently enhance zinc 
inhibition of NMDARs.  
 
3.5 Material and Methods 
3.5.1 Neuronal cultures 
All animal procedures used in experiments were approved by the Institutional Animal Care 
and Use Committee of the University of Pittsburgh School of Medicine. Cortical cultures were 
prepared from embryonic day 16 rats. Briefly, pregnant rats (Charles River Laboratory) were 
sacrificed via CO2 inhalation. Embryonic cortices were dissociated with trypsin and plated at 
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670,000 cells per well on glass coverslips in six-well plates. Non-neuronal cell proliferation was 
inhibited after 2 weeks in culture with cytosine arabinoside (1–2 μM). Cultures were utilized at 3–
4 weeks in vitro. 
3.5.2 MRE-Luciferase reporter assay 
Mixed cortical cultures were transfected at 19-20 DIV with MRE-firefly luciferase reporter 
(pLuc-MCS/4MREa), and Renilla luciferase reporter (pRLTK). Renilla was used as a non-
inducible reporter as a control for transfection efficiency. Cells were transfected with the plasmids 
(1 µg pLuc-MSC/4MREa, 0.4 µg pRLTK, 0.1 µg pBK-CMV) using Lipofectamine 2000. Twenty-
four hours later, cells were treated with 250 nM pyrithione (a zinc ionophore) or 250 nM pyrithione 
with 10 µM ZnCl2 in DMEM containing 2% calf serum and 25 mM HEPES. Twenty-four hours 
after treatment, both firefly and Renilla luciferase expression were measured using the Dual-Glo 
Luciferase Assay System (Promega). Results were expressed as the ratio of firefly luciferase 
activity to Renilla luciferase activity, as described previously (Hara & Aizenman, 2004). 
3.5.3 Proximity ligation assay 
Proximity ligation assays were performed using Duolink PLA kit. Cortical cultures (3–4 
weeks in vitro) were treated overnight with either N2AZ or scN2AZ (3 µM, dissolved in water), 
and pyrithione (250 nM), or zinc pyrithione (10 µM ZnCl, 250 nM pyrithione) . Coverslips were 
fixed in ice cold methanol for 5 minutes, rinsed in phosphate buffered saline (PBS) then 
permeabilized with 0.1% Triton-X in PBS. Coverslips were then incubated with primary 
antibodies: rabbit anti-ZnT1, mouse anti-GluN2A, and chicken anti-MAP2. Coverslips were 
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incubated with a donkey anti-chicken fluorescent secondary antibody targeting MAP2 antibodies 
to visualize neuron morphology. The PLA reaction was then completed according to DuoLink 
PLA protocol. Briefly, coverslips were incubated in DuoLink secondary antibodies (anti-rabbit 
and anti-mouse) which are conjugated with complementary oligonucleotides. Ligation solution 
was added to hybridize connector oligonucleotides and PLA probes, allowing the oligonucleotides 
to join in a closed loop when secondary antibodies were in close proximity. Next, the reaction was 
amplified with rolling-circle amplification (RCA) using the closed loop hybridized probes as a 
template. PLA probes were fluorescently labeled with oligonucleotides which hybridized to the 
RCA product during amplification. Coverslips from sister cultures were treated with either 
scN2AZ, N2AZ and pyrithione or zinc pyrithione and reactions were run simultaneously using the 
same preparation of reagents. Coverslips were mounted on glass slides using DuoLink mounting 
media and 4 random fields of view were imaged from each coverslip using a 60x oil objective on 
a Nikon A1R laser scanning confocal. PLA puncta were counted automatically with Fiji ImageJ 
(Version 2.0) software. We used maximum intensity projection of 15 sequential images in the z 
plane. All images were thresholded using Yen threshold setting prior to automated quantification 
of puncta. The ratio of puncta per field of view in ZnPyr versus Pyr treated conditions was taken 
between sister coverslips that were treated, fixed, and assayed with the same PLA preparation.  
3.5.4 Electrophysiology 
Whole-cell recordings from cultured cortical neurons were obtained with glass 
micropipettes (3-6 MΩ) containing (in mM): 140 CsF, 10 CsEGTA, 1 CaCl2, 10 HEPES, pH = 
7.2, 295 mOsm. Extracellular recording solution contained (in mM): 150 NaCl, 2.8 KCl, 1.0 
CaCl2, 10 HEPES, 60 µM glycine, pH = ~7.2 , ~300 mOsm. Using Ephus (Suter et al., 2010)  and 
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a Multiclamp 700B amplifier (Molecular Devices), NMDAR EPSCs were recorded in voltage 
clamp (holding potential -70 mV) in the presence of TTX (300 nM, sodium channel blocker), 
DNQX (20 µM, AMPA and kainate receptor antagonist), and 4-Methoxy-7-nitroindolinyl (MNI)-
caged glutamate (40 µM). To evoke NMDAR EPSCs, we photolytically uncaged MNI-caged 
glutamate using 1 ms pulses of UV-laser light (355 nm, DPSS Lasers). The ZX1-mediated 
potentiation for each cell was calculated as the percent increase in average response (10 sweeps, 
before and after ZX1) following application of the metal chelator. 
3.5.5 Statistical Analyses 
Electrophysiology recordings were obtained using Ephus (Suter et al., 2010) software run 
in Matlab 2012a (MathWorks). Cell parameters and response peaks were calculated using custom 
Matlab scripts. For electrophysiology, ZX1 potentiation was measured as the percent increase in 
NMDAR amplitude 10 minutes after the application of ZX1.  Unpaired t-tests and ANOVAs were 
used to compare between treatments. Statistical analysis was completed in Prism 8 (GraphPad).  
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4.0 Discussion 
This dissertation uncovered a novel postsynaptic mechanism that drives zinc inhibition of 
NMDARs. These findings challenge existing models that assume that diffusion of vesicular zinc 
across the synaptic cleft is sufficient to modulate postsynaptic NMDA receptors. We discovered 
that ZnT1’s interaction with GluN2A is necessary for endogenous zinc inhibition, even in the 
presence of presynaptic release of vesicular zinc. Disrupting this association or chelating 
intracellular zinc is sufficient to significantly reduce endogenous inhibition. Furthermore, we 
found that increasing intracellular zinc content upregulates ZnT1-dependent zinc inhibition. 
Together these results reveal that multiple zinc-regulatory systems cooperate to maintain zinc 
inhibition of NMDARs. These findings expand on our understanding of the complex mechanisms 
that regulate zinc signaling within neurons. 
 
Based on our results, we hypothesize a new model for zinc inhibition of NMDARs in which 
ZnT1 localizes zinc in the proximity of the receptor through its direct interaction with the GluN2A 
subunit (Figure 19). This model is supported by our finding that disrupting the association between 
GluN2A and ZnT1 reduces zinc inhibition, however there are some important caveats that should 
be noted. Our model assumes that N2AZ’s action is specific to ZnT1’s association with GluN2A. 
Although we determined that N2AZ did not alter presynaptic glutamate release, the IC50 of zinc, 
or ZnT1 transport, it is possible that N2AZ may disrupt other proteins’ associations with GluN2A-
containing NMDARs. The C-terminal domain of GluN2 subunits is a common site for protein 
interactions including those that contribute to receptor scaffolding and downstream signaling 
(Hardingham, 2019). The N2AZ sequence may overlap with regions where other proteins bind to 
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GluN2A, therefore disrupting their association and consequent signaling. Another caveat to our 
findings is we do not know how the association between GluN2A and ZnT1 influences either 
protein’s surface expression. A previous study showed that silencing ZnT1 led to increased 
internalization of GluN2A subunits in hippocampal neurons (Mellone et al., 2015). This finding 
suggests that the interaction with ZnT1 may serve to stabilize GluN2A-containing NMDARs in 
the membrane, therefore N2AZ may influence zinc sensitivity of neurons by reducing the surface 
expression of GluN2A-containing NMDARs.  
 
Another factor to consider for the interpretation of our findings is the broader impact of 
zinc chelation and genetic knockdown of ZnT3 on neuronal function. We used ZX1 for its high 
affinity and fast kinetics, which allows it to chelate zinc transients generated by presynaptic 
vesicular zinc release. However, this high affinity chelation may also serve to strip zinc from lower 
affinity protein binding sites, therefore influencing zinc-regulated signaling in neurons beyond its 
inhibition of NMDARs. In particular, intracellular ZX1 may disrupt zinc binding to signaling 
proteins, such as kinases such as Src (Huang et al., 2008), which can influence NMDAR expression 
through phosphorylation of GluN2 subunits (Manzerra et al., 2001). Another limitation to consider 
is the impact of ZnT3 knockout on neuronal zinc signaling. Although knockouts are the most direct 
means of disrupting vesicular zinc, it is unclear if or how these knockout animals compensate for 
the lack of ZnT3 over the course of their development. For example, it is possible that in the 
absence of vesicular zinc release, ZnT3 knockout animals differentially express ZnT1 or other 
transporters to maintain zinc signaling. Therefore, further investigations are necessary to validate 




Figure 19 Model of N2AZ Action 
Legend for Figure 19: Model of N2AZ Action. We propose that the association between ZnT1 and 
GluN2A localizes zinc in the proximity of NMDARs to drive zinc inhibition (top) through binding 
to the high affinity site on the N-terminal of GluN2A. When this association is disrupted using 
N2AZ (bottom), NMDARs are dissociated from the microdomain of zinc thus reducing 
endogenous zinc inhibition of the receptor.  
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4.1 Translocation of Vesicular Zinc 
A significant unanswered question in our model is what is the relationship between ZnT3-
dependent presynaptic release and postsynaptic transport by ZnT1. The simplest model to account 
for our observations is that vesicular zinc translocates into postsynaptic cells where it is then 
transported by ZnT1 to extracellular microdomains in the immediate vicinity of GluN2A. 
Consistent with this hypothesis, it has been shown that electrical or pharmacological stimulation 
of hippocampal neurons leads to transient increases in post-synaptic intracellular zinc that are 
dependent on extracellular zinc levels (Li et al., 2001; Ha et al., 2018).  This suggests that vesicular 
zinc can translocate into the postsynaptic neuron following activity-dependent presynaptic release. 
 
Multiple channels have been identified that mediate zinc translocation from vesicular stores 
to the postsynaptic neuron, including calcium-permeable AMPA receptors (CP-AMPARs), 
NMDA receptors (NMDARs), and voltage-gated calcium channels (VGCCs) (Figure 20). 
AMPARs were first linked to zinc transport with the observation that AMPAR activation increases 
zinc toxicity (Weiss et al., 1993). Furthermore, zinc uptake selectively labels neurons that express 
CP-AMPARs and this subpopulation of neurons is more susceptible to zinc-toxicity (Yin & Weiss, 
1995; Yin et al., 1998). Direct measurement of zinc current through CP-AMPARs established that 
the receptor conducts zinc even in the presence of physiological calcium (Jia et al., 2002). In 
addition to CP-AMPARs, voltage gated calcium channels mediate zinc-toxicity and zinc influx 
following depolarization with high potassium (Manev et al., 1997; Sheline et al., 2002). 
Electrophysiological recordings confirmed VGCCs conduct zinc (Kerchner et al., 2000a), with L-
type CaV1.2 and CaV1.3 isoforms, but not CaV2 or CaV3 isoforms, being permeable zinc to the ion 
(Park et al., 2015). Zinc also permeates through NMDARs, but to a lesser extent than calcium 
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(Koh & Choi, 1994). NMDARs mediate increases in zinc following treatment with low 
micromolar zinc concentrations, suggesting that vesicular zinc released into the cleft reaches 
concentrations sufficient to permeate the receptor (Marin et al., 2000). In this project, neither 
AMPARs or LTCCs were necessary for endogenous zinc inhibition of NMDARs, suggesting they 
are not essential links between ZnT3-dependent release and ZnT1 transport. However, it is possible 
that, under certain circumstances, zinc influx through these channels could activate MTF-1 to 
upregulate ZnT1 expression. In fact, zinc influx through LTCC was shown to drive expression of 
genes under the MRE-driven metallothionein promoter, albeit in a pituitary tumor cell line (Atar 
et al., 1995). Therefore, LTCCs may indirectly alter ZnT1-dependent inhibition by driving zinc 
upregulation of ZnT1. 
 
Transient receptor potential channels (TRPs) can also mediate zinc translocation into 
neurons. For example, TRPM7 channel inhibition or genetic knockdown reduces intracellular zinc 
and zinc toxicity in mouse cortical cultures (Inoue et al., 2010). Interestingly, there are multiple 
examples of TRP channels coupling zinc influx to channel modulation. For instance, TRPM7 is 
necessary for extracellular zinc mediated activation of BK channels, which have intracellular zinc 
binding sites (Hou et al., 2010). Similarly, zinc influx through TRPA1 mediates zinc inhibition of 
TRPV1 and subsequent reduction of acute nociception in dorsal root ganglion neurons (Luo et al., 
2018).  TRPA1 itself mediates zinc influx required for its own activation by zinc binding to 
intracellular residues (Hu et al., 2009). This suggests a shared mechanism in which TRP channels 
localize zinc influx to downstream signaling targets of zinc. Further studies are needed to 
determine if TRP channels directly contribute to zinc pools necessary for ZnT1-mediated 
inhibition of NMDARs.  
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Another possible conduit of vesicular zinc translocation into the postsynaptic neuron are 
ZIP transporters (Figure 20). Many ZIP transporters are localized in the plasma membrane 
suggesting they may play a role in postsynaptic import of vesicular zinc after release (Kambe et 
al., 2015). In the brain, ZIP1 and ZIP3 contribute to zinc-mediated degeneration in the CA1 region 
of the hippocampus following kainate-induced seizures. Animals with ZIP1 and ZIP3 knockout 
exhibit reduced CA1 damage compared to controls resulting from decreased zinc uptake (Qian et 
al., 2011). Similarly, ZIP1 and ZIP4 upregulation following kainate injections in the hippocampus 
leads to increased zinc import into neurons (Emmetsberger et al., 2010). Little is known about ZIP 
transporter function in neurons under non-pathological conditions; therefore, further investigation 
is needed to understand if and how ZIP transporters contribute to regulation of zinc within the 
synaptic cleft.  
4.2 Intracellular Zinc Release 
Transient increases in intracellular zinc can also occur independent of translocation of 
vesicular zinc. For example, zinc accumulation in degenerating neurons occurs in regions of the 
brain that do not express ZnT3 (Lee et al., 2000; Land & Aizenman, 2005; Medvedeva et al., 
2017). This suggests an additional pool of zinc can be mobilized to regulate synaptic function by 
supplying intracellular zinc for ZnT1 or to drive ZnT1 expression via MTF1. These ZnT3- 
independent intracellular zinc signals result from liberation of zinc from intracellular stores, such 
as zinc-binding proteins or subcellular organelles.  
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Intracellular zinc is buffered by intracellular proteins, notably metallothioneins. 
Metallothioneins are critical buffers of intracellular zinc with 20 cysteine residues per 
metallothionein protein that bind up to 7 zinc ions via metal-thiolate clusters (Maret & Krezel, 
2007). Of the four metallothionein isoforms, three (MT-I through MT-III) are expressed in the 
central nervous system, with MT-III the primary form expressed in neurons (Aschner et al., 1997). 
These proteins release zinc in response to oxidative stimuli (Maret, 1994; 1995). For example, the 
thiol oxidant 2,2’-dithiodipyridine (DTDP) triggers intracellular zinc release from MTs and 
subsequent zinc-dependent cell death in cortical neurons in vitro (Aizenman et al., 2000). 
Glutamate also has been shown to trigger the generation of reactive oxygen species through 
NMDAR-mediated calcium influx and subsequent mitochondrial dysfunction. Therefore, 
glutamate-dependent reactive oxygen species generation may represent an activity-dependent 
mechanism driving zinc release from MTs (Reynolds & Hastings, 1995; Aizenman et al., 2000). 
Nitric oxide, an endogenous gas, also liberates zinc from MTs (Lin et al., 2007), likely through its 
interaction with superoxide and production of peroxynitrite (Zhang et al., 2004). Following 
ischemic injury, inhibitors of NO synthase prevent the accumulation of intracellular zinc which 
suggests that NO endogenously mobilizes zinc from intracellular stores (Wei et al., 2004). 
Notably, neuronal NO synthase  (nNOS) activation is directly coupled to NMDAR-mediated 
calcium influx through nNOS’s interaction with postsynaptic density protein 95, which suggests 
NMDAR activation itself can drive NO-mediated zinc release (Zhou et al., 2010). Furthermore, 
glutamate-induced intracellular acidification drives proton-dependent release of zinc from zinc-
binding proteins (Kiedrowski, 2012; 2014). Thus, multiple activity-dependent mechanisms 
liberate zinc from metal-binding proteins which may subsequently regulate postsynaptic zinc 
levels and ZnT1-mediated NMDAR inhibition.  
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Zinc can also be released from subcellular organelles, including the endoplasmic reticulum 
(ER) and Golgi apparatus. The ER sequesters zinc following increases in cytosolic levels in 
cortical neuron cultures (Qin et al., 2011). Zinc can be released from the ER following activation 
of the IP3 receptor or inhibition of the ER calcium pump with thapsigargin (Figure 20) (Stork & 
Li, 2010; Qin et al., 2011). Therefore, IP3 signaling through Gq-coupled metabotropic receptors, 
such as mZnR or metabotropic glutamate receptors, may trigger increases in intracellular zinc. 
Alternatively, zinc can be released from the ER and Golgi apparatus by the transporter ZIP7 
(Figure 20). Phosphorylation of ZIP7 by protein kinase CK2 triggers intracellular zinc release 
(Taylor et al., 2012; Nimmanon et al., 2017). Interestingly, ZIP7 phosphorylation occurs following 
treatment of cells with 20 µM extracellular zinc, suggesting an additional possible mechanism by 
which release of vesicular zinc could drive intracellular zinc transients (Taylor et al., 2012). 
Lysosomes also can accumulate zinc. Knockdown of TRPML1 leads to enlargement of and zinc 
accumulation in lysosomes, suggesting that TRPML1 may endogenously release zinc from these 
stores (Figure 20) (Eichelsdoerfer et al., 2010; Kukic et al., 2013). In fact, studies using the high-
affinity zinc sensor GZnP3 found that activation of TRPML1 led to zinc release from 
endolysosomal compartments in neurites of hippocampal neuron cultures (Minckley et al., 2019). 
 
Together these examples illustrate that multiple mechanisms increase intracellular zinc 
without relying on direct transport of released vesicular zinc into the postsynaptic cell. This raises 
the intriguing possibility that ZnT1-mediated inhibition occurs at synapses that do not have 
presynaptic ZnT3. Indeed, we observed zinc inhibition in cortical cultures using glutamate 
uncaging, which does not engage presynaptic release mechanisms. However, this leads to the 
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question, why is ZnT3-dependent release necessary for zinc inhibition in the DCN (Anderson et 
al., 2015)? One distinct possibility is that the dominant source of intracellular zinc arises from 
translocation of vesicular zinc to postsynaptic neurons, as discussed above. Another possibility is 
that zinc acts as a signal to elicit liberation of zinc from intracellular stores. For example, zinc is 
released from IP3-sensitive stores (Stork & Li, 2010), suggesting that mZnR activation and 
subsequent IP3 signaling is capable of eliciting intracellular zinc release. Alternatively, ZnT3 may 
be necessary for determining overall zinc content of intracellular stores in postsynaptic neurons. 
In this hypothesis, ZnT3-dependent release and translocation primes postsynaptic structures with 
sufficient levels of zinc that can be released from intracellular stores following physiological 
stimuli. Consistent with this, deletion of ZnT3 leads to a marked decrease in zinc staining 
throughout the brain (Cole et al., 1999), suggesting that vesicular pools are an essential source of 
labile zinc in the brain. Therefore, a dynamic relationship between postsynaptic intracellular zinc 




Figure 20 Model of Zinc Transport and Release at the Synapse 
Legend for Figure 20: Model showing the various routes of entry of zinc into the cell and 




4.3 Function of ZnT1-mediated Zinc Inhibition of NMDARs 
Our experiments suggest that ZnT1 organizes zinc into distinct microdomains in the 
proximity of GluN2A-containing NMDARs to regulate inhibition. These microdomains may allow 
for precise control over zinc localization and concentration to target NMDARs without also 
affecting other zinc signaling pathways. Consistent with this, disrupting ZnT1’s association with 
GluN2A had no effect on endogenous zinc inhibition of AMPARs. In recent years, investigation 
of the organization of pre- and postsynaptic protein complexes has revealed synaptic 
nanostructures can critically influence transmission and plasticity (Biederer et al., 2017). For 
example, voltage gated calcium channels create microdomains of calcium in the proximity of 
synaptic vesicles to precisely control presynaptic release (Berridge, 2006). Furthermore, alignment 
of presynaptic vesicle release sites and postsynaptic AMPAR creates a trans-synaptic 
‘nanocolumn’ that is hypothesized to precisely regulate neurotransmission (Tang et al., 2016; 
Biederer et al., 2017). It is reasonable to infer that zinc, which is co-released from glutamatergic 
vesicles, exhibits similar dynamics to preferentially targets receptors aligned to release sites, such 
as AMPARs. Therefore, postsynaptic ZnT1 may redistribute ZnT3-dependent zinc to receptors 
that are distal to release sites, such as peri- or extrasynaptic receptors. NMDARs are located 
extrasynaptically at the parallel fiber to cartwheel cell synapse in the DCN, where we observed 
ZnT1-dependent zinc inhibition (Anderson et al., 2015). Extrasynaptic versus synaptic activation 
leads to differential activation of postsynaptic signaling cascades and gene expression. Notably, 
extrasynaptic NMDARs are hypothesized to mediate cell death signaling whereas synaptic 
activation is associated with pro-survival signaling (Hardingham & Bading, 2010; Parsons & 
Raymond, 2014). Therefore ZnT1-mediated inhibition may serve to preferentially modulate 
extrasynaptic NMDARs and subsequent downstream signaling.  
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NMDAR function is also influenced by subunit composition. NMDAR subunits exhibit 
differential expression patterns across development, brain regions, and cell types and are coupled 
to distinct signaling consequences (Paoletti et al., 2013). Notably, subunit composition impacts 
the induction and direction of NMDAR-mediated plasticity. Subunit specific manipulations induce 
metaplasticity by shifting the ratio of GluN2A to GluN2B activation to influence the threshold for 
induction of plasticity (Yashiro & Philpot, 2008). Because ZnT1 specifically binds to the GluN2A 
C-terminal domain (Mellone et al., 2015), it may mediate metaplasticity by driving preferential 
inhibition of GluN2A. Consistent with this hypothesis, it has been shown that zinc inhibition of 
GluN2A regulates the magnitude of LTP at the mossy fiber to CA1 synapse in the hippocampus 
(Vergnano et al., 2014). ZnT1 overexpression or knockdown leads to a respective increase or 
decrease in spine length and width (Mellone et al., 2015), which is a correlate of synaptic strength 
(Matsuzaki et al., 2004). In this dissertation, we showed that ZnT1-mediated inhibition is 
dynamically regulated by intracellular zinc, which can increase in response to synaptic activity 
(Sanford & Palmer, 2020). Therefore, intracellular zinc, ZnT1, and subsequent GluN2A inhibition 
may cooperatively regulate activity-dependent changes in synaptic strength. 
4.4 ZnT1 as a Target for Neuroprotection 
NMDARs contribute to excitotoxic cell death in variety of pathological conditions, 
including ischemic stroke and neurodegenerative diseases (Hardingham & Bading, 2010). 
However, they are also essential for pro-survival signaling, synaptic transmission, and plasticity 
(Peters et al., 1987). This dual role of the receptor makes blocking NMDAR for neuroprotection 
challenging. Therefore, the focus for therapeutic strategies has turned to targeting specific receptor 
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subpopulations and downstream signaling consequences (Wu & Tymianski, 2018). We found that 
ZnT1 drives zinc inhibition of extrasynaptic NMDARs, which are hypothesized to preferentially 
couple to cell death signaling (Hardingham & Bading, 2010). Therefore, ZnT1 may be a useful 
target for reducing excitotoxic cell death. 
 
One effective mechanism that reduces excitotoxic cell death is preconditioning, a process 
in which sublethal insults trigger endogenous neuroprotective cascades that mitigate damage from 
subsequent injuries. Zinc signaling has been implicated in neuronal preconditioning. Zinc itself is 
sufficient to precondition neurons against NMDA-induced toxicity (Lee et al., 2008; Lee et al., 
2015b). A rise in cytosolic zinc is necessary for an in vitro model of ischemic preconditioning in 
cortical cultures (Aras et al., 2009). Furthermore, this preconditioning model also drives MRE-
dependent gene expression. Together this suggests that zinc-driven proteins, such as ZnT1 may be 
critical for the expression of preconditioning. Consistent with this, ZnT1 is upregulated following 
sub-lethal transient ischemia in rat cerebral cortex and hippocampus (Aguilar-Alonso et al., 2008). 
Together this points to ZnT1 upregulation and subsequent inhibition of NMDARs as a potential 
mechanism underlying preconditioning.  
 
Beyond its role in excitotoxicity, zinc is also hypothesized to contribute to Alzheimer’s 
disease (AD) through its interaction with Aβ, the primary component of amyloid plaques (Huang 
et al., 2000). This ‘Metal Hypothesis of Alzheimer’s Disease’ proposes that zinc, along with other 
transition metals such as copper, drive Aβ pathogenicity (Bush & Tanzi, 2008). This is based, in 
part, on the observation that vesicular zinc promotes the aggregation and accumulation of Aβ in 
the synapse  (Bush et al., 1994; Deshpande et al., 2009) and modulating zinc levels, through 
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chelators or ZnT3 knockouts, reduces Aβ aggregation (Bush & Tanzi, 2008). Zinc binding to Aβ 
is also hypothesized to dysregulate neuronal zinc homeostasis (Sensi et al., 2009), which is 
supported by the observation that localization and expression of zinc transporters are altered in 
AD models and postmortem brain tissue of AD patients (Xu et al., 2019). Based on these findings, 
metal chaperones have been developed as potential therapeutics for the treatment of AD (Adlard 
& Bush, 2018). Metal chaperones bind extracellular zinc and transport it into the cytoplasm, and 
therefore serve to both reduce zinc-driven accumulation of Aβ and redistribute dysregulated zinc. 
  
Metal chaperones drive pro-survival signaling via intracellular zinc-dependent cascades 
(Crouch et al., 2011). Notably, treatment with the chaperone PBT2 preconditions cells against 
excitotoxic insults in a zinc-dependent manner (Johanssen et al., 2015).  NMDAR dysfunction and 
excitotoxicity have been linked to Aβ-driven pathology in Alzheimer’s disease (Danysz & Parsons, 
2012), therefore ZnT1-mediated inhibition of NMDARs may contribute to the protective effects 
of metal chaperones in AD models. A similar chaperone, clioquinol, was identified an activator of 
MTF-1, implicating chaperones in the upregulation of MRE-driven proteins, such as ZnT1 
(Jackson et al., 2020). Together this suggests that zinc driven ZnT1 expression and NMDAR 
inhibition may contribute to the efficacy of metal chaperones in the treatment of AD. 
4.5 ZnT1 as a Target in NMDAR Dysfunction 
Zinc and NMDAR signaling are both implicated for the regulation of pain. NMDARs 
contribute to regulation of pain sensitivity (Petrenko et al., 2003) and reducing NMDAR signaling 
suppresses both inflammatory and neuropathic pain (Liu et al., 2008). Mice with a knock-in 
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mutation on GluN2A that removes high affinity zinc binding exhibit hypersensitivity to pain 
stimuli, suggesting that endogenous zinc inhibition of NMDARs attenuates pain processing 
(Nozaki et al., 2011). Consistent with this, a spinal nerve transection model of neuropathic pain 
leads to reduced ZnT3 expression and synaptic zinc in the spinal cord, correlated to increased pain 
sensitivity (Jo et al., 2008). A similar model, partial sciatic nerve ligation, downregulates ZnT1 
expression in the spinal cord, suggesting a correlation between ZnT1 expression and pain 
(Kitayama et al., 2016). In fact, ZnT1 knockdown alone is sufficient to induce neuropathic pain 
symptoms (Kitayama et al., 2016). Together, this suggests that ZnT1-mediated zinc inhibition of 
NMDARs in the spinal cord may regulate pain sensitivity. Furthermore, upregulation of ZnT1 via 
MTF1 may be a useful mechanism to investigate for the treatment of chronic pain.  
 
Zinc dysregulation has been observed in patients and animal models of Autism Spectrum 
Disorder (ASD). Zinc deficiency is commonly observed in ASD patients (Yasuda et al., 2011; 
Pfaender et al., 2017). Furthermore, both maternal zinc deficiency and ZnT3 knockout leads to 
ASD-like phenotypes in mice (Grabrucker et al., 2014; Grabrucker et al., 2016; Yoo et al., 2016). 
It is hypothesized that zinc contributes to ASD through to its role in stabilization of the post-
synaptic density scaffolding proteins Shank2 and Shank3. Zinc binds to the sterile alpha motif 
(SAM; a putative protein interaction domain (Thanos et al., 1999)) on the C-terminal of Shank2/3 
to regulate its oligomerization and localization (Arons et al., 2016). Dietary zinc supplementation 
is sufficient to ameliorate ASD-associated behaviors such as anxiety, repetitive behaviors, and 
social deficits in Shank 3 knockout models of ASD (Fourie et al., 2018; Vyas et al., 2020).  In 
addition to these behavioral improvements, Shank 3 knockout models exhibit reductions in 
NMDAR currents and slower NMDAR decays (Fourie et al., 2018). This may be indicative of a 
 93 
reduction in GluN2A-mediated current, as GluN2A imparts fast decay kinetics on NMDARs 
(Paoletti et al., 2013). Furthermore, clioquinol improves social interaction and modifies NMDAR 
activity in mouse models of ASD by increasing cytosolic zinc (Lee et al., 2015a). Together this 
suggests that both cytosolic zinc availability and NMDARs are viable targets for modifying 
synaptic and behavioral dysfunction associated with ASD. ZnT1, which regulates both of these 
systems, stands out as a potential candidate for manipulating synaptic dysfunction associated with 
ASD.     
 
Schizophrenia is also associated with dysregulation of both zinc and NMDAR signaling. 
The glutamatergic theory of schizophrenia hypothesizes that NMDAR hypofunction contributes 
to synaptic and circuit dysfunction in schizophrenia (Marek et al., 2010). Consistent with this idea, 
NMDAR antagonists mimic schizophrenic symptoms in healthy adults and post-mortem tissue of 
schizophrenic patients exhibit decreased GluN1 expression (Hardingham & Do, 2016). 
Interestingly de novo mutations in GRIN2A, the gene encoding the GluN2A subunit, are 
associated with schizophrenia (Hardingham & Do, 2016). Single nucleotide polymorphisms 
associated with schizophrenia have been identified in multiple zinc transporters, including ZIP8, 
and ZIP13 (Fullard et al., 2019) (Hess et al., 2016) (Kranz et al., 2015). Furthermore, post mortem 
tissue from patients with schizophrenia exhibit elevated ZIP12 expression in the cerebral cortex 
(Scarr et al., 2016). This indicates that increased zinc import via ZIPs may be associated with the 
development of schizophrenia. We demonstrated that increases in intracellular zinc upregulate 
ZnT1-mediated NMDAR inhibition. Therefore, zinc-driven expression of ZnT1 and subsequent 
inhibition of NMDARs may be a unique mechanism linking zinc dysregulation and NMDAR 
hypofunction in schizophrenia. 
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4.6 Conclusion 
There is a growing appreciation for the role of zinc signaling in both physiological and 
pathological functions in the brain. Despite zinc’s widespread distribution and diversity of targets 
in the brain, much remains unclear about zinc’s dynamics at the synapse. This dissertation reveals 
a novel mechanism of zinc regulation via postsynaptic ZnT1. ZnT1’s association with the GluN2A 
of NMDAR critically contributes to endogenous zinc inhibition of NMDARs, which is further 
driven by intracellular zinc signals. This dynamic coupling of intracellular zinc, ZnT1, and 
GluN2A represent a complex mechanism of regulation that maintains NMDAR inhibition. Given 
the diverse functions of NMDARs, this system may serve as a novel target to modulate neuronal 
function in both health and disease.  
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Appendix A Endogenous extracellular zinc is neuroprotective against excitotoxicity  
Appendix A.1 Overview 
Excitotoxicity is a neurodegenerative process in which NMDAR overactivation leads to a 
lethal calcium influx and subsequent cell death. Excitotoxic cell death contributes to damage in a 
variety of disorders, including stroke, traumatic brain injury, and neurodegenerative diseases 
(Parsons & Raymond, 2014).  Zinc is a potent inhibitor of NMDARs and application of zinc 
protects against excitotoxic damage (Peters et al., 1987). In the brain, zinc is loaded into synaptic 
vesicles via the transporter ZnT3 and is co-released with glutamate to modulate neurotransmission 
(Sensi et al., 2009). It has been shown that this vesicular zinc endogenously inhibits NMDARs 
(Pan et al., 2011; Anderson et al., 2015). Furthermore, an additional ZnT3-independent pool of 
zinc has been measured that endogenously inhibits extrasynaptic NMDARs (Anderson et al., 
2017). Given that extrasynaptic NMDARs receptors are thought to be preferentially linked to 
excitotoxicity (Parsons & Raymond, 2014), we investigated whether tonic zinc acts as an 
endogenous signal that limits excitotoxicity via its inhibition of NMDARs. 
Appendix A.2 Results 
To start investigating the role of tonic zinc in excitotoxicity and NMDAR inhibition, we 
first measured extracellular zinc concentrations in rat cortical cultures using the ratiometric 
fluorescent zinc probe, LZ9. This probe has both zinc sensitive (ZP1) and zinc insensitive (LRB) 
 96 
fluorescence that are excited by blue and green light respectively (Figure 21A, B). Excitation of 
the zinc-sensitive ZPI domain was interleaved with excitation of the zinc-insensitive LRB domain 
to consistently measure the change fluorescence of both domains over time. The ratio of ZP1 
fluorescence to LRB fluorescence provides a measure of zinc-dependent fluorescence. After 
measuring baseline fluorescence, the dynamic range of the probe is obtained by adding EDTA to 
get minimum fluorescence ratio followed by ZnCl2 to get maximum fluorescence. Together these 
values can be used to calculate the concentration of extracellular zinc using the equation in Figure 
21C. Using this method, we measured ~0.4 nM tonic zinc in cortical cultures, consistent with the 






Figure 21 Nanomolar extracellular concentrations of zinc are present in cortical cultures 
Legend for Figure 21: (A) Schematic of the ratiometric fluorescent probe, LZ9. (B) Emission 
profiles of the zinc-sensitive ZP1 and zinc-insensitive LRB domains of LZ9. Adapted from 
Anderson et al., 2015. (C) Equation used to determine the concentration of extracellular zinc using 
the baseline (Rtonic), maximum (Rmax), and minimum (Rmin) fluorescence in combination with the 
dissociation constant of LZ9. (D) Example trace of the ratio of ZP1:LRB fluorescence over time 
in an experiment. (E) Average zinc concentration in cortical culture preparations 
 
Next, we tested whether endogenous extracellular zinc is protective during excitotoxicity. 
We used the glutamate uptake inhibitor DL-threo-β-benzyloxyaspartic acid (TBOA, 75 µM) to 
increase extracellular glutamate and thus promote excitotoxic cell death. TBOA treatment alone 
induced a significant increase in cell death compared to untreated controls as measured with LDH 
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assay (Figure 22B, Repeated measures one-way ANOVA, p < 0.0001, Bonferroni’s Multiple 
comparisons, p = 0.015). Furthermore, TBOA induced cell death could be blocked with the 
NMDAR antagonist memantine (50 µM) indicating that TBOA-induced damage was NMDAR 
dependent (Figure 22C). We assessed if endogenous zinc protected against excitotoxicity by 
chelating extracellular zinc with the high-affinity, cell-impermeant chelator ZX1. ZX1 
significantly increased TBOA-induced cell death compared to TBOA treatment alone (Figure 22B, 
p = 0.048), indicating that endogenous zinc protects against excitotoxicity. Furthermore, the cell 
death observed in all condition was completely blocked with memantine, indicating that cell death 
is NMDAR dependent (Figure 22C). To visualize the effect of these treatments, neurons were 
transfected with green fluorescent protein (GFP) prior to treatment (Figure 22A). These results 





Figure 22 Extracellular zinc protects against excitotoxicity 
Legend for Figure 22: (A) Representative images of GFP transfected neurons demonstrate 
excitotoxic damage for each treatment group. (B) LDH assay showing relative cell death across 
treatment groups. TBOA induced cell death compared to vehicle controls (p = 0.015) and 
significantly increased cell death when comparing ZX1 and ZX1+TBOA treated neurons (p < 
0.0001). ZX1 treatment enhanced TBOA cell death compared to TBOA alone (p = 0.048) (C) 
LDH results for the same groups in the presence of NMDA receptor antagonist, memantine, 
indicating no significant differences between treatments (One-way ANOVA, p = 0.418) 
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Appendix A.3 Conclusions 
These results indicate that tonic, nanomolar levels of zinc are present in cortical cultures 
and dampen excitotoxic damage through their inhibition of NMDARs. Although it is documented 
that application of zinc can reduce NMDAR-mediate toxicity (Peters et al., 1987), these results 
suggest this protection also occurs with endogenous zinc pools. We measured low nanomolar 
concentrations of zinc present in our cortical culture preparation, which is sufficient to occupy the 
high-affinity zinc binding site on GluN2A-containing NMDARs. In light of our recent finding that 
ZnT1 regulates zinc inhibition of NMDARs, this nanomolar zinc measurement may represent an 
underestimation of zinc levels in the immediate vicinity of GluN2A (Chapter 2). We hypothesized 
that ZnT1 organizes zinc into microdomains that specifically concentrate zinc near NMDARs, and 
therefore the local concentration and subsequent inhibition may be higher than what is measured 
for the entire coverslip. Interestingly, ZnT1 expression and subsequent NMDAR inhibition is 
upregulated by intracellular zinc signals (Chapter 3). This suggests that endogenous extracellular 
zinc levels regulated by ZnT1 dynamically increases in response to intracellular zinc state. 
Together these results provide evidence that endogenous zinc signaling mechanisms may be useful 
targets for neuroprotection against excitotoxicity.  
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Appendix A.4 Methods 
Appendix A.4.1 Ratiometric Zinc Imaging 
To determine the concentration of extracellular zinc in cortical cultures described above, 
the ratiometric zinc probe LZ9 (2 µM) was used as previously described (Anderson et al., 2015). 
Zinc sensitive (blue excitation) and zinc-insensitive (green excitation) fluorescence was evoked 
using an interleaved pattern of excitation. Fluorescence was monitored continually until a steady 
state (Rtonic) was observed, at which point EDTA (4.5 mM) was added to achieve minimum Zn2+ 
fluorescence (Rmin), followed by ZnCl2 (5 mM) to saturate the probe for maximum Zn2+ 
fluorescence (Rmax). Ratiometric fluorescence was calculated by taking the ratio of Zn2+ sensitive: 
Zn2+ insensitive fluorescence. Total extracellular Zn2+ concentration was calculated using the 





Appendix A.4.2 Neuronal Cultures and LDH Assay 
All animal procedures used in experiments were approved by the Institutional Animal Care 
and Use Committee of the University of Pittsburgh School of Medicine. Cortical cultures were 
prepared from embryonic day 16 rats. Briefly, pregnant rats (Charles River Laboratory) were 
sacrificed via CO2 inhalation. Embryonic cortices were dissociated with trypsin and plated at 
670,000 cells per well on glass coverslips in six-well plates. Non-neuronal cell proliferation was 
inhibited after 2 weeks in culture with cytosine arabinoside (1–2 μM). Cultures were utilized at 3–
4 weeks in vitro. Following overnight treatment with the glutamate uptake inhibitor TBOA (50 
 102 
µM), the zinc chelator ZX1 (3 µM) and/or the NMDAR antagonist memantine (50 µM), cell 
viability was assessed using a lactate dehydrogenase (LDH) release assay (TOX-7 in vitro 
toxicology assay kit; Sigma). To visualize cell morphology, neurons were transfected with green 
fluorescent protein (GFP) using 2 µL Lipofectamine 2000, 100 µL Opti-MEM media, and 1.5 µg 
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